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Abstract 
Protein S-acylation, the only fully reversible post-translational lipid modification of proteins, is 
emerging as a ubiquitous mechanism to control the properties and function of a diverse 
array of proteins and consequently physiological processes.  S-acylation results from the 
enzymatic addition of long chain lipids, most typically palmitate, onto intracellular cysteine 
residues of soluble and transmembrane proteins via a labile thioester linkage.  Addition of 
lipid results in increases in protein hydrophobicity that can impact on protein structure, 
assembly, maturation, trafficking and function. The recent explosion in global S-acylation 
(palmitoyl) proteomic profiling as a result of improved biochemical tools to assay S-acylation, 
in conjunction with the recent identification of enzymes that control protein S-acylation and 
de-acylation, has opened a new vista into the physiological function of S-acylation.  This 
review introduces key features of S-acylation and tools to interrogate this process, and 
highlights the eclectic array of proteins regulated including: membrane receptors, ion 
channels and transporters, enzymes and kinases, signaling adapters and chaperones, cell 
adhesion and structural proteins.  We highlight recent findings correlating disruption of S-
acylation to pathophysiology and disease and discuss some of the major challenges and 
opportunities in this rapidly expanding field. 
 
I. Introduction 
Cellular proteins are regulated by a diverse range of chemical modifications on their amino 
acid sidechains (Figure 1). These various modifying groups can affect charge, 
hydrophobicity, and other aspects of protein chemistry, resulting in marked changes in the 
behaviour of protein molecules and hence in the control of physiological mechanisms. 
Lipidation is a general term encompassing the attachment of different lipids and lipid-like 
groups onto proteins (144, 208). These lipid modifications increase protein hydrophobicity 
and can impact on protein structure and the affinity of proteins for cellular membranes or 
membrane domains. 
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Glycosylphosphatidylinositol (GPI) groups anchor many cellular proteins to the outer surface 
of the plasma membrane, and cholesterol is attached to certain secreted proteins (60, 91, 
208).. For proteins retained inside the cell, common lipidations are fatty acylation and 
isoprenylation (208). The latter modification involves the post-translational attachment of 
farnesyl and geranygeranyl chains onto C-terminal cysteine residues via an irreversible 
thioether linkage (208, 269).. The enzymes farnesyl transferase and geranylgeranyl 
transferase I UHFRJQLVHDVWULFW ³CAAX´ (A is any aliphatic amino acid and X is any amino 
acid) consensus motif present at the extreme C-terminus of proteins. The amino acid 
occupying the X position in the CAAX motif determines if the protein is modified by farnesyl 
transferase or geranylgeranyl transferase I (134, 269). A different geranylgeranylation signal 
(non-CAAX) is recognised by the enzyme geranylgeranyl transferase II, which modifies Rab 
proteins (135). 
The main types of fatty acylation characterised to-date are N-myristoylation and S-acylation. 
N-myristoylation most frequently involves the co-translational reaction of myristic acid with a 
glycine residue in the consensus sequence MGXXXS/T (where M is the initiating methionine 
and X is any amino acid) (8, 25, 208). As myristoyl chains are added to the amine group of 
the glycine, this modification requires the previous removal of the initiating methionine 
residue (65). N-myristoylation does not occur exclusively as a co-translational modification, 
and can also take place post-translationally when N-terminal glycine residues are exposed 
following protein cleavage, for example, during apoptosis (264). 
S-acylation has proved more enigmatic than isoprenylation and N-myristoylation, however 
recent breakthroughs have shed light on the mechanisms and dynamics of this modification. 
S-acylation is exclusively post-translational, involving the attachment of fatty acids onto 
cysteine residues via a labile thioester linkage and thus, in contrast to other lipidations, S-
acylation may be dynamic and reversible (Figure 2) (51, 144, 208, 215, 221, 232). This 
modification is frequently referred to as palmitoylation, reflecting the fact that palmitate is the 
predominant fatty acid attached to S-acylated proteins. Historically, S-acylation was 
relatively difficult to study due to the low sensitivity of available detection methods, the 
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absence of a defined consensus sequence and a dearth of information about the relevant 
enzymes responsible for this lipid modification (167). However recent breakthroughs have 
identified the S-acylation enzymes and developed highly sensitive techniques to study this 
process, leading to a marked increase in our knowledge of the mechanisms and outcomes 
of protein S-acylation.  
 
In this review we first outline some general features of S-acylation including its ubiquity, 
reversibility and diversity of substrates before outlining some of the key regulatory effects S-
acylation may have on protein function and subcellular localisation. We then review the 
enzymatic control of S-acylation and the implication of S-acylation in disease and outline 
methodologies exploited to assess and interrogate S-acylation. Finally, we discuss selected 
examples to highlight the diverse array of cellular proteins and physiological processes 
controlled by S-acylation ± from control of gene transcription and cellular architecture to ion 
flux across membranes - before highlighting some of the key outstanding questions in the 
field. 
  
II. General Features of S-Acylation 
 
II.i S-acylation is a universal modification in eukaryotes 
S-acylation is a highly conserved process occurring in all eukaryotic organisms that have 
been examined, and regulated by enzyme families (Figure 2) that are conserved from yeast 
to humans (74, 122, 167, 212). Proteomic profiling of S-acylated proteins in the yeast 
Saccharomyces cerevisiae identified 47 acylated proteins (212), whereas similar studies 
have detected several hundred S-acylated proteins in mammalian and other cell types (30, 
83, 108, 118, 122, 139, 155-157, 162, 265, 266, 268, 276, 278, 282). The number of S-
acylated proteins identified in these studies may well be a significant under-representation, 
as techniques employed to enrich the S-acylated proteome may be affected by the level and 
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dynamics of S-acylation on individual proteins. Whilst there is no evidence for S-acylation 
occurring in prokaryotes, many viral proteins undergo S-acylation catalysed by the host cell 
machinery, and indeed analysis of viral protein S-acylation has made a significant 
contribution to current knowledge about S-acylation in general e.g. (129). 
 
II.ii S-acylation is a reversible modification 
A key property of S-acylation that distinguishes it from other lipid modifications of cellular 
proteins is its reversibility. The labile nature of thioester bonds in the intracellular 
environment allows many (but not all) S-acylated proteins to undergo rapid cycles of S-
acylation and deacylation (215). Classically, S-acylation dynamics have been studied using 
radiolabelling with [3H] palmitic acid, which is converted into [3H] palmitoyl-coA in cells and 
incorporated into S-acylated proteins. Early studies that employed [3H] palmitate pulse-
chase experiments highlighted the reversibility of S-acylation, for example the half-life of 3H 
palmitate incorporated into N-Ras was shown to be around 20 minutes (154). These 
radiolabelling experiments have been instrumental in defining cellular S-acylation dynamics, 
however it is possible that this approach does not provide sufficient sensitivity to generate 
highly accurate turnover rates; for example, more recent work using an indirect reporter of S-
acylation status suggested that deacylation of N-Ras may occur 10-20 times faster than 
calculated by pulse-chase analyses (209, 210). These apparent differences will require 
future clarification through the use of multiple approaches to determine palmitate turnover 
dynamics. The dynamic nature of S-acylation may therefore be more akin to other post-
translational modifications that can have rapid turnover rates, such as phosphorylation, and 
cycles of S-acylation and deacylation are now known to play a fundamental role in regulating 
the intracellular localisation and function of many diverse proteins (215) (see section VI). 
The reversibility of S-acylation sets this process apart from other lipid modifications and 
implies an important role for S-acylation in the dynamic regulation of cellular proteins. 
Nevertheless, it needs be emphasised that rapid cycling of acyl chains on S-acylated 
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proteins is not universal, and S-acylation turns over at a very low rate or not at all on other 
cellular proteins (157). Indeed marked differences can exist in the turnover rates of different 
S-acylation sites in the same protein (294). Thus, a major outstanding question in S-
acylation research relates to how the dynamics of lipid turnover on S-acylated proteins is 
regulated and why different proteins display distinct turnover rates. 
 
II.iii Diversity of Lipid Groups Attached to S-Acylated Proteins 
7KHWHUP µSDOPLWR\ODWLRQ¶ is often used synonymously with µS-acylation¶7KLVQRPHQFODWXUH
stems from the multitude of studies that have monitored S-acylation via incorporation of [3H] 
palmitate into specific cellular proteins. Nonetheless, it is likely that palmitate (C16:0) is 
indeed the major lipid incorporated into endogenous S-acylated proteins, although other fatty 
acids such as stearate (C18:0) and oleate (C18:1) can also be added (253). One study used 
gas chromatography-mass spectrometry to quantify the different fatty acids that were 
released from total platelet proteins following hydroxylamine treatment (which cleaves 
thioester bonds between acyl groups and cysteine). This quantification found that of the fatty 
acids added to proteins via S-acylation, on average 74% were palmitate, 22% were stearate 
and 4% were oleate (174). This study provides a snap-shot of the lipid diversity on S-
acylated proteins, but it is important to emphasise that there are likely to be other fatty acids 
incorporated at lower levels, and different cell types will likely exhibit distinct lipid profiles as 
will individual S-acylated proteins. Indeed the lipid profile of S-acylated proteins in platelets 
was markedly affected by the lipid composition of the extracellular environment, and there 
was also marked variability in the level of oleate in platelets from different subjects (at 
maximum, 100-fold) (174). Studies using cell lines have highlighted similar heterogeneity in 
fatty acids attached via S-acylation (140). 
The challenge of dissecting the chemical identity of the lipid groups added to S-acylated 
proteins is widely recognised. The study described above employed gas chromatography-
mass spectrometry to quantify the levels of individual lipids on platelet proteins, and this 
technique can also be applied to analyse the lipid profile of individual S-acylated proteins 
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(234); however this approach is not able to determine the exact cysteine residues that are 
modified by the detected fatty acids. However tandem mass spectrometry approaches have 
proved useful to profile the lipid species that are attached to specific cysteine residues in 
viral proteins. These analyses have revealed that the haemagluttinin protein of Influenza 
viruses can be modified by both palmitate and stearate, and intriguingly that stearate 
appears to be specifically added to cysteines located within the transmembrane domains of 
these proteins (128, 129). Whilst mass spectrometry approaches hold significant promise to 
dissect acyl chain heterogeneity in S-acylated proteins, technical hurdles have thus far 
prevented widespread use of this methodology, in particular for most low abundance 
mammalian membrane proteins. 
 
II.iv.  Diversity of S-Acylation Substrates 
Proteomic profiling of S-acylated proteins from a variety of different cell types has revealed 
the diverse nature of the modified proteins (see section VI) (30, 83, 108, 118, 122, 139, 155-
157, 162, 265, 266, 268, 276, 278, 282). S-acylated proteins can be broadly classified as 
transmembrane or peripheral membrane proteins, with the latter requiring acylation for 
stable membrane binding (Figure 3). Peripheral membrane S-acylated proteins often 
XQGHUJRµGXDO¶OLSLGPRGLILFDWLRQDQGWKXVFDQEHIXUWKHUVXE-classified accordingly as either: 
N-myristoylated/S-acylated, isoprenylated/S-acylated, or exclusively S-acylated (232). 
Exemplar proteins that are modified in these three ways include Src family kinases, Ras 
proteins, and the membrane fusion protein SNAP25, respectively (82, 98, 127). 
Transmembrane proteins that are modified by S-acylation are equally as diverse in nature as 
the S-acylated peripheral membrane proteins, and include ion channels, receptors and 
transporters (122). 
 
 
III. Regulatory Effects of S-Acylation 
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S-acylation has been implicated in the control of multiple stages of the lifecycle of 
transmembrane and peripheral-membrane proteins (Figure 4): from protein assembly to 
trafficking and final degradation. 
 
III.i Membrane binding of peripheral membrane proteins 
For peripheral membrane proteins, the first and foremost function of S-acylation is to 
mediate stable membrane attachment (215). This requirement for S-acylation to promote 
stable membrane binding holds even for dual lipidated proteins, as single myristoyl or prenyl 
groups are not sufficient in this regard. Seminal work exploring the interaction of lipidated 
peptides with modeO PHPEUDQHV XQFRYHUHG D IXQGDPHQWDO SULQFLSOH WHUPHG µNLQHWLF
WUDSSLQJ¶ (222).  These studies revealed that single myristoyl or prenyl groups only provide 
peptides with a weak membrane affinity, sufficient for transient membrane binding. In 
contrast, closely positioned dual lipid anchors, (either myristate/palmitate or 
farnesyl/palmitate) mediate strong, essentially irreversible, membrane-peptide interaction. 
This kinetic trapping observed when peptides convert from having a single lipid group to 
being dual lipidated is highly relevant when one considers the intracellular distribution of 
lipidating enzymes. N-myristoyl and prenyl transferases, which mediate the co- and post-
translational modification of soluble proteins, respectively, are localised in the cell cytosol (5, 
26, 125, 254). In contrast, the enzymes that mediate S-acylation are exclusively membrane-
associated (see section IV) and as a result this modification only occurs at cellular 
membranes. Thus, N-myristoylation or prenylation of proteins during or shortly after their 
synthesis in the cytosol bestows a weak membrane affinity that mediates transient 
interaction with intracellular membranes. These transient membrane interactions allow singly 
lipidated proteins to connect with membrane-bound S-acyl transferases, and subsequent S-
acylation leads to stable membrane binding and kinetic trapping. The requirement of dual 
lipidation for stable membrane binding has been clearly shown for a variety of cellular 
proteins; for example, mutation of the S-acylation site(s) in Ras proteins leads to a weak 
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association with membranes, whereas mutation of the farnesylation signal leads to a loss of 
both S-acylation and membrane binding (81). 
As mentioned previously, some proteins are exclusively S-acylated with no obvious primary 
membrane targeting signals. It has been suggested that such proteins rely upon a weak 
intrinsic membrane affinity to access intracellular membranes and undergo S-acylation and 
thus a similar kinetic trapping idea holds for these proteins. This mechanism of initial 
membrane interaction has been proposed to operate for SNAP25 and CSP (77, 78). 
Although transmembrane proteins are irreversibly membrane-integrated, S-acylation of 
cysteine residues in the cytoplasmic domains of these proteins can dictate the membrane 
proximity of these domains (Figure 3). This can have a major effect on the overall 
structure/topology of the protein relative to the membrane. 
 
III.ii Targeting to membrane micro-domains and sub-domains 
The lipids within cellular membranes are diverse and have been proposed to undergo short-
range ordering, as a result of packing preferences. This concept is readily observed in model 
membrane systems composed of ternary lipid mixtures, where cholesterol and saturated 
phospholipids phase separate from unsaturated phospholipids (20). This phase separation 
that occurs in vitro has been proposed to also occur in intact cellular membranes, leading to 
the formation of cholesterol- and saturated phospholipid-rich microdomains (229). It has 
been incredibly challenging to study these so-called lipid rafts in live cells due to the small 
size of these structures (<50 nm) (199) and several investigators have questioned whether 
such domains ever form or have meaningful functions in cellular membranes (173). The 
functions and composition of lipid rafts have largely been ascribed based upon results using 
cholesterol depletion experiments and detergent-insolubility as a descriptor for raft-
associated proteins. Although there is intense debate about the extent to which detergent 
solubility characteristics of membrane proteins reflect association with cholesterol-rich lipid 
raft domains (141), it is clear that S-acylated proteins largely co-purify with cholesterol-
enriched detergent insoluble membranes (161). As a result, S-acylation has been proposed 
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as an important signal for sequestration into lipid raft micro-domains, and thus as a regulator 
of the lateral distribution of proteins within membranes (136). S-acylation-dependent 
association of proteins with detergent-insoluble rafts has been proposed to regulate 
important cellular pathways such as exocytosis via the membrane fusion protein SNAP25 
(214)  and actin cytoskeleton remodelling and membrane organisation via Rac1 (176). 
Progress in this area of research is likely to be substantially enabled by the development of 
super-resolution imaging techniques that provide optical resolution on the order of raft size 
(49). 
The majority of work on membrane microdomains has focussed on proteins associated with 
the plasma membrane, however intracellular compartments also exhibit heterogeneities in 
structure and composition. The endoplasmic reticulum (ER) is a case in point, and 
diversification of this compartment into several distinct sub-domains facilitates its role as a 
multi-functional organelle (152).  Protein S-acylation appears to be an important factor in 
targeting proteins to specific ER sub-domains. Calnexin, which functions in the folding of 
glycoproteins in the ER, is S-acylated at the cytoplasmic side of its single transmembrane 
domain (132). Perturbing acylation of calnexin decreased the association of this protein with 
the ribosome-studded rough ER surrounding the nuclear envelope (132). Molecular 
modelling of the calnexin transmembrane domain and a short cytoplasmic region suggested 
that S-acylation may modify the orientation of the cytoplasmic tail with respect to the axis of 
the transmembrane helix (132), and these structural changes may facilitate targeting of 
calnexin, albeit by a presently unknown mechanism. A role for S-acylation has also emerged 
in targeting of proteins to the mitochondrial-associated membrane (MAM) another distinct 
ER sub-domain. The transmembrane thioredoxin family protein TMX and heme oxygenase-1 
were found to require S-acylation for efficient targeting to the MAM (150). This study also 
suggested that S-acylation of calnexin was required for targeting to the MAM (150), and thus 
more work is clearly required in this area to understand the precise requirements and 
mechanisms whereby S-acylated proteins are segregated to defined domains in the ER. 
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III.iii Protein trafficking and intracellular localisation 
S-acylation regulates the trafficking and localisation of a wide range of cellular proteins (72). 
Many effects on protein trafficking and localisation are likely to be attributable to the impact 
of S-acylation on membrane binding and micro-localisation discussed above. S-acylation will 
affect the localisation of peripheral membrane proteins simply by promoting accumulation of 
modified proteins on membranes containing the respective acylation enzymes. This S-
acylation-dependent movement of proteins from the cytosol to membranes may allow other 
domains of the protein to interact with sorting adaptors, mediating trafficking to distinct 
membrane compartment(s). In this scenario, S-acylation is required for protein trafficking (by 
virtue of the requirement of this modification for membrane association) but it does not 
actively direct proteins to a specific intracellular compartment. 
,QDGGLWLRQ WR WKHVH µSDVVLYH¶ HIIHFWVRI S-acylation on protein localisation, S-acylation can 
also function as an active protein sorting signal. Short peptides from the lipidated C-terminus 
of H/N-Ras display a similar localisation to the full-length proteins, implying that lipid signals 
may be sufficient to specify movement of Ras proteins from endomembranes to the plasma 
membrane (80). At present it is not clear how S-acylation might regulate trafficking of these 
peptides but this may involve effects of S-acylation on protein micro-localisation. For 
example, cholesterol-rich domains at the Golgi have been proposed to act as platforms for 
the budding of transport vesicles delivering cargo to the plasma membrane (188). Thus, S-
acylation might promote Golgi exit by driving protein association with such cholesterol-rich 
microdomains. 
It can be challenging to tease apart the active effects of S-acylation on trafficking of 
peripheral membrane proteins from the requirement of this modification for stable membrane 
binding. However for multiply-acylated proteins such as the SNARE protein SNAP25, it is 
possible to examine effects of individual S-acylated cysteines on protein trafficking, without 
interfering with membrane binding. Indeed, recent work has suggested that the extent of S-
acylation of SNAP25 (4 potential acylation sites) regulates the cycling of this protein between 
the plasma membrane and endosomes (73), which may impact endosomal fusion dynamics 
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(7). In this case, mutant SNAP25 proteins with 3 rather than 4 S-acylation acceptor sites 
exhibited a marked accumulation on endosomal membranes (73), likely highlighting a role 
for the extent of S-acylation in regulating endosome-to-plasma membrane trafficking of 
SNAP25. The mechanistic basis underlying the effects of multiple S-acylation on SNAP25 
endosomal cycling are not known, however the number of acylation acceptor sites in 
SNAP25 has a marked effect on association of the protein with cholesterol-rich membranes 
(213), suggesting that lipid rafts might feature in the regulation of this cycling pathway. 
As transmembrane proteins do not require S-acylation for stable membrane binding, the 
importance of this modification for trafficking is potentially easier to dissect. As a result, we 
currently have a clearer picture about the active effects of S-acylation on the trafficking of 
integral membrane proteins. 
During protein translation, signal peptides and start/stop transfer sequences are employed to 
insert transmembrane proteins into the membrane of the endoplasmic reticulum (ER) and 
generate the required topological arrangement of the protein with respect to the membrane 
bilayer (223). Various chaperones and enzymes in the ER lumen facilitate protein folding, 
catalyse modifications such as glycosylation, and support oligomeric assembly of proteins 
into the necessary quaternary structure (237). S-acylation has been reported to regulate 
trafficking of a variety of transmembrane proteins from the ER (72, 215), including LRP6, a 
co-receptor for Wnt. LRP6 is a monotopic transmembrane protein that is S-acylated close to 
the cytoplasmic side of the membrane-spanning domain (1). LRP6 proteins with the S-
acylation sites mutated were retained at the ER and failed to traffic to the plasma membrane. 
Intriguingly, this block in forward trafficking of S-acylation-deficient mutants was alleviated by 
reducing the length of the TMD of LRP6. This observation suggests that S-acylation may 
KDYH WKH HIIHFW RI µUHGXFLQJ¶ WKH DSSDUHQW OHQJWK RI WKH /53 70' 7KXV WKH DXWKRUV
proposed that non-acylated LRP6 is trapped at the ER because hydrophobic mismatching 
occurs between the long TMD (23 amino acids) and the thin ER bilayer, and that S-acylation 
improves hydrophobic matching by inducing the TMD to tilt with respect to the membrane 
axis.  Recent molecular dynamics simulations have supported the idea of interactions 
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between S-acyl chains and transmembrane helices, with the two S-acyl chains attached to 
the C-terminus of the G protein-coupled receptor rhodopsin reported to make frequent 
contacts with a transmembrane helix of the protein (183).  
A similar role for S-acylation in regulating ER exit was described for the yeast chitin 
synthase, Chs3, a polytopic membrane protein. In this case, blocking S-acylation was found 
to promote aggregation and ER retention and a similar role for acylation in hydrophobic 
matching was proposed (133). Although the ER membrane has relatively low levels of 
cholesterol (or the yeast equivalent, ergosterol), S-acylation might also facilitate hydrophobic 
matching by targeting the modified protein into thicker cholesterol-rich domains on the ER 
membrane. A recent report also suggested that S-acylation may regulate the expression and 
localisation/maturation of both wild type and 'F508 CFTR (159), highlighting a potential 
therapeutic role for drugs that modify S-acylation for the treatment of cystic fibrosis. 
In addition to these effects of S-acylation on trafficking of newly-synthesised proteins, there 
are also numerous reports that this modification regulates movement of proteins between 
the plasma membrane and endosomal system. Again, it is difficult to find a consensus model 
to predict, for a specific protein, how S-acylation might modulate trafficking between the 
plasma membrane and endosomes. S-acylation in the C-terminus of AMPA receptor 
subunits regulates internalisation from the plasma membrane, and the mechanism involves 
the modulation of receptor interaction with the cytoskeletal protein 4.1N (86, 142).  S-
acylation of NMDA receptor subunits also regulates internalisation of this neurotransmitter 
receptor (87). However in this case, this results from downstream effects of S-acylation on 
phosphorylation of a tyrosine residue involved in receptor internalisation; S-acylation 
enhances phosphorylation, blocking internalisation and hence leading to receptor 
accumulation at the plasma membrane. In addition to effects of S-acylation on protein 
internalisation from the plasma membrane, there is also evidence that this modification can 
regulate recycling of proteins from endosomes back to the plasma membrane. This was 
observed for MUC1, a mucin-like protein present on the apical membrane of epithelia. MUC1 
containing cysteine-to-alanine mutations at the transmembrane boundary that block S-
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acylation exhibited an enhanced accumulation at recycling endosomes. In addition, the 
mutant protein displayed reduced co-immunoprecipitation with the adaptor protein AP1, 
which regulates vesicle formation at recycling endosomes, offering some mechanistic insight 
into how perturbation of S-acylation might impact MUC1 recycling (126). There is also 
evidence that S-acylation impacts the cycling of sortillin between endosomes and the Golgi 
apparatus. Sortillin is involved in the trafficking of soluble proteins from the Golgi to 
lysosomes, and cycles between the Golgi and endosomsal compartment. In this case, 
blocking palmitoylation interfered with trafficking of Sortillin back to the Golgi complex and 
led to enhanced degradation of the protein in lysosomes (160). S-acylation mutants of 
Sortillin appear to be more susceptible to ubquitination, explaining their increased targeting 
to lysosomes and degradation(47).  
 
III.iv.  Protein stability 
Increased ubiquination and degradation is commonly observed when S-acylation of specific 
proteins is blocked. This interplay between S-acylation and ubiquitination was reported for 
the yeast SNARE protein Tlg1 (257). This protein is S-acylated in proximity to its single 
transmembrane domain and preventing this modification by deleting the relevant zDHHC 
enzyme (Swf1) leads to increased ubiquitination by the ubiquitin ligase Tul1 and vacuole 
targeting. In this case, S-acylation was suggested to fix the position of the transmembrane 
domain to prevent acidic residues coming into membrane contact, which can be a scenario 
leading to Tul1-mediated ubquitination. A similar interplay between S-acylation and 
ubiquitination has been identified for many other proteins including the anthrax toxin receptor 
TEM8 (2). S-acylation is thought to restrict TEM8 to non-raft domains of the plasma 
membrane, whereas S-acylation mutants associate with lipid rafts and undergo 
ubiquitination mediated by Cbl. The effect of S-acylation to restrict raft association of TEM8 
is in contrast to the raft-targeting activity of this modification on many other proteins. These 
two examples given for Tlg1 and TEM8 emphasise how S-acylation can protect against 
premature degradation via distinct mechanisms: by preventing membrane interaction of 
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negatively charged phospholipids for Tlg1 and by regulating the lateral distribution in 
membranes for TEM8. 
It is interesting to note that the limited number of proteomic analyses performed to-date in 
mouse lines with reduced expression of S-acyltransferase enzymes (zDHHC enzymes) have 
also noted that reduced S-acylation levels of specific proteins often correlates with an overall 
loss of expression. We anticipate that careful proteomic assessment of how S-acylation 
affects the expression levels of the cellular proteome will provide a detailed understanding of 
how widespread the link between S-acylation and protein stability is. 
 
III.v. Functional effects of S-acylation from studies in mouse models and disease 
Cell-based studies have highlighted the importance of S-acylation for the function of 
individual proteins in specific cellular pathways. For example, the extent of S-acylation 
dictates the lateral distribution of the membrane fusion protein SNAP25 in cholesterol-rich 
plasma membrane micro-domains, which affects the efficiency of regulated exocytosis in 
neuroendocrine cell (213, 214). Perturbing the S-acylation of calnexin results in a loss of the 
protein from the perinuclear rough ER, which is enriched in ribosome-translocon complexes, 
with a corresponding defect in folding of cellular glycoproteins (132). More global 
physiological effects of S-acylation are reflected in the phenotypes of genetically modified 
mice with perturbations in specific S-acyl transferases (74)  (see Table 1 and zDHHC 
enzymes, section IV.i.).  
zDHHC5 genetrap mice with low expression levels of this enzyme have perturbed contextual 
fear conditioning, which indicates a deficit in learning and memory (138). The molecular 
basis for this behavioural change is not known but might be linked to interactions of zDHHC5 
with post-synaptic proteins such as PSD95 (138)  and GRIP1b (244). zDHHC8 knockout 
mice also exhibit behavioural abnormalities including changes in pre-pulse inhibition and in 
exploratory behaviour (172); these deficits may be caused by underlying changes in the 
formation/stability of excitatory synapses and perturbations in dendritic growth (171). 
zDHHC17 and zDHHC13 genetrap mice also exhibit behavioural deficits and changes in 
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neuronal function (230, 240). These highly-related enzymes S-acylate the huntingtin (HTT) 
protein (105), and furthermore zDHHC17 activity is positively modulated by HTT (106). 
Expansion of the poly-glutamine tract of HTT DVVHHQLQ+XQWLQJWRQ¶VGLVHDVH, HD) leads to 
a loss of S-acylation and also a reduced ability to regulate zDHHC17 S-acylation activity 
(106, 273), implying that changes in HTT S-acylation or its regulation of zDHHC enzymes 
might contribute to the deficits present in HD. The idea that loss of zDHHC17 activity might 
contribute to pathogenesis in HD is supported by recent work showing that zDHHC17 
genetrap mice (insert at intron 5) display similar deficits as HD mouse models. The 
zDHHC17 mutant mice exhibit decreased striatal volume and a loss of medium spiny 
neurons, a reduction in the number of excitatory synapses, and a deficit in hippocampal 
long-term potentiation (164, 230). At the behavioural levels, the mice display deficits in motor 
co-ordination, pre-pulse inhibition, and hippocampal-dependent spatial learning tests (164, 
230). Biochemically, zDHHC17 genetrap mice exhibit a partial loss of SNAP25 and PSD95 
S-acylation (230), although it is not yet clear if these substrates contribute to the cellular and 
behavioural changes present in the mice. Given the strong homology between zDHHC17 
and zDHHC13 it is likely that HTT can also regulate the activity of this latter enzyme. Indeed, 
zDHHC13 genetrap mice (insert in intron 1) exhibit a broadly similar neuropathology to 
zDHHC17 genetrap mice (240). Furthermore, the phenotypic changes seen in zDHHC13 
mutant mice, such as a decreased striatal volume, occur later and are more progressive 
than in zDHHC17 mutant mice and as such mirror HD mouse model phenotypes better 
(240). 
Other zDHHC mouse models that have been investigated include a different zDHHC13 loss-
of-function mouse line, which expresses a truncated form of the zDHHC13 protein exhibits 
skin and hair defects (216). Furthermore, the mice also display a reduced life-span, systemic 
amyloidosis, osteoporosis and muscle wasting (216), with recent work linking the 
osteoporosis phenotype with a reduced S-acylation of membrane type 1- matrix 
metalloproteinase (233). Interestingly, no HD-like phenotype was seen in this zDHHC13 
mouse model (233), unlike in the zDHHC13 genetrap model (240). A major difference 
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between these two zDHHC13 mouse lines is that one is hypomorphic whereas the other 
expresses a truncated (and therefore possible dominant-negative) form of the enzyme. 
Finally, a mouse line with a point mutation in the zdhhc21 gene exhibits hair loss and skin 
abnormalities (163). The mutation in the zdhhc21 gene leads to a single amino acid 
substitution in zDHHC21 and a resulting mis-localisation of the enzyme on ER rather than 
Golgi membranes (163). Future work on these and other zDHHC mutant mice will hopefully 
include an analysis of knock-in mutants in which the catalytic cysteine is mutated. This will 
be an important step to resolve effects arising due to a loss of S-acylation activity of the 
zDHHC enzymes from other non-canonical functions of the zDHHC proteins. 
The reported phenotypes of zDHHC mutant mice clearly show the importance of individual 
enzymes for normal physiology. This is further emphasised by the reported links between 
human diseases and mutations in ZDHHC genes or changes in zDHHC expression levels 
(Table 2). Mutations in the ZDHHC9 gene cause X-linked intellectual disability (ID) (202). 
Importantly, two point mutations linked with ID led to single amino acid changes in the 
DHHC-CR domain of zDHHC9, and these mutations have since been shown to affect 
enzyme autoacylation (a measure of activity) in in vitro assays (165). This provides strong 
evidence that intellectual disability can arise due to a deficit in the S-acylation of specific 
substrates of zDHHC9 rather than because of any other non-canonical functions of this 
enzyme. It will therefore be important in future work to identify proteins that have reduced S-
acylation following inactivation of the zDHHC9 enzyme and to explore whether loss of these 
proteins leads to features seen in intellectual disability. 
Despite earlier work reporting an association between an SNP in the ZDHHC8 gene and an 
increased risk of developing schizophrenia (145), the majority of follow-up studies have 
failed to support such an association (270). However more recent work has suggested a 
possible link between zDHHC8 SNPs and smooth pursuit eye movement (which is perturbed 
in schizophrenia patients) (224)  and cortical brain volume in schizophrenics (184). 
Thioesterase enzymes, which catalyse protein deacylation, also have a critical role in brain 
function. This is exemplified by mutations in the PPT1 gene, which cause infantile neuronal 
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ceroid lipofuscinosis (NCL), an early-onset neurodegenerative lysosomal-storage disease. 
PPT1 encodes a protein palmitoyl thioesterase that functions in the degradation of S-
acylated proteins in lysosomes (262). 
In addition to brain disorders such as intellectual disability, schizophrenia and NCL, there is 
also evidence linking changes in zDHHC expression, both up- and down-regulation, with 
various cancers. For example, the ZDHHC11 gene is present within a region of chromosome 
5 that has an increased copy number in lung and bladder cancers (120, 271)  and zDHHC9 
expression is increased in colorectal tumours (16). In contrast, zDHHC2 has been reported 
to be down-regulated in colorectal cancers (186)  and also in gastric adenocarcinoma (272), 
and zDHHC14 expression is down-regulated in testicular germ cell tumours and prostate 
cancer (280). These findings may suggest a potential tumour suppressor function of 
zDHHC2 and zDHHC14, however it is worth noting that increased zDHHC14 expression was 
seen in gastric cancer and leukaemia (11, 283), suggesting that this protein actually might 
be oncogenic in certain settings. 
A major area of investigation should now centre on delineating the substrate(s) of zDHHC 
enzymes that are linked with specific disease states. This would lead to a greater 
understanding of the specific proteins and physiological pathways that are likely to be 
affected by changes in zDHHC function. It should also be remembered that in come cases, 
diseases may be linked with up- or down-regulation of non-canonical activities of zDHHC 
enzymes. 
 
IV. Acylation Enzymes and the Control of Acylation 
 
IV.i. S-acyl transferases: zDHHCs 
The biggest breakthrough in the S-acylation field in recent years was the discovery of the 
enzymes that control this process. Independent studies in Saccharomyces cerevisiae 
identified proteins that were required for S-acylation of Ras2p and Yck1p (14, 147, 211, 
21 
 
287). Analysis of the sequences of these S-acyl transferases, Erf2p and Akr1p, revealed a 
FRPPRQDPLQRDFLG]LQFILQJHUGRPDLQZLWKDFRQVHUYHGµ'++&¶PRWLIQRWHWKLVPRWLILV
actually DYHC in Akr1p) (167). This pioneering work in S. cerevisiae paved the way for the 
subsequent discovery of a large family (24 in human genome) of mammalian genes 
encoding proteins containing this DHHC domain (61, 107, 124). It is now established that the 
large majority of these mammalian zDHHC proteins are bona fide S-acyl transferases (74, 
109). However it is important to note that other acylation-independent functions have 
additionally been ascribed to some members of the family, including in membrane transport, 
intracellular signalling, and cytoskeletal regulation (42, 69, 101, 274). Experiments using 
purified zDHHC proteins are consistent with the idea that S-acylation by these enzymes is a 
two-step mechanism involving autoacylation of the DHHC motif cysteine and subsequent 
acyl transfer to the substrate protein (112, 166). 
All zDHHC family members characterised to-date are predicted polytopic membrane proteins 
with the catalytic DHHC domain facing the cytosol (Figure 2C) (196). The majority of zDHHC 
proteins are localised to ER and Golgi membranes, with a small number present on post-
Golgi compartments (182). At present there is little information available on the 
intramolecular signals that specify intracellular localisation, although lysine-based sorting 
signals in the extreme C-terminal tails of zDHHC4 and zDHHC6 restrict these specific 
isoforms to the ER (68).  
Whilst zDHHC enzymes are likely to display a certain degree of redundancy and have 
partially over-lapping substrates, it is also true that specific substrates are dependent upon 
individual zDHHC enzymes for their efficient modification. Proteomic analyses following 
knockdown of individual zDHHC enzymes in S. cerevisiae clearly highlighted that efficient S-
acylation of specific substrates requires individual zDHHC enzymes (212). In concurrence, 
other focussed studies showed that deletion of Pfa4 led to an ablation of S-acylation of the 
chitin synthase Chs3 (133)  and Swf1p deletion blocked S-acylation of the SNARE protein 
Tlg1p (257). Furthermore, S-acylation of Tlg1 following depletion of Swf1 was not rescued by 
high level expression of three other yeast zDHHC proteins, although Pfa3 had a modest 
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effect on S-acylation of this SNARE protein (67). Similarly, S-acylation of Chs3p was not 
rescued by either Swf1, Pfa3 or Erf2 (67). Indeed, specific zDHHC enzymes are required for 
the S-acylation of different sites on the same protein, for example this is true for the STREX 
variant of BK potassium channels (248, 249). However superimposed upon this zDHHC-
substrate specificity is an element of zDHHC enzymes acting on over-lapping substrates 
(74). Thus, VAC8 S-acylation in an S. cerevisiae strain depleted of the zDHHC protein Pfa3 
could be rescued by over-expression of other yeast zDHHC enzymes (104), and analysis of 
semi-synthetic Ras constructs suggested that multiple zDHHC enzymes could regulate S-
acylation of these proteins (209). However a key point to note is that although several 
zDHHC enzymes might be able to S-acylate a specific substrate, the enzymes that are 
important in vivo will depend upon their relative expression profiles; thus distinct zDHHC 
enzymes might be important for the S-acylation of a specific substrate in different cell types. 
Despite the debate around the level of specificity in zDHHC-substrate interactions, several 
studies have identified domains and residues in both substrates and enzymes that are 
important for interaction specificity. The catalytic DHHC-CR domain does not appear to be 
sufficient for substrate S-acylation or to specificity substrate selectivity, This point is 
emphasised by a study showing that although zDHHC3 is highly active against SNAP23, 
transplanting the DHHC domain from this protein into an inactive enzyme (zDHHC15) did not 
allow zDHHC15 to acylate SNAP23 (75). Instead, zDHHC enzyme protein activity likely 
requires the coordinated activities of the DHHC domain and other regions of the enzyme. 
zDHHC17 and zDHHC13 (also known as HIP14 and HIP14L, respectively) are unique in 
containing N-terminal ankyrin repeat domains, which appear to specify substrate binding 
(281). Indeed ligating the ankyrin-repeat domain of zDHHC17 onto the N-terminus of 
zDHHC3 led to the S-acylation of zDHHC17 substrates by zDHHC3, highlighting the 
importance of this protein interaction domain for substrate recognition and subsequent S-
acylation (105). The S. cerevisiae orthologue of zDHHC17, Akr1p, also contains an ankyrin-
repeat extension, and although mutants lacking the ankyrin repeat domain were able to S-
acylate Yck2p, the extent of this acylation was greatly reduced compared with full-length 
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Akr1p (94). More recent work showed that a PDZ ligand in the C-terminus of 
zDHHC5/zDHHC8 regulates binding to and S-acylation of GRIP1b, an adaptor protein 
containing multiple PDZ domains (244). Combined depletion of these zDHHC5 and zDHHC8 
led to an almost complete loss of GRIP1b acylation in hippocampal neurons (244). Thus, at 
least some zDHHC enzymes recognise their substrates via defined domains, which then 
couple with the DHHC-CR domain to mediate substrate S-acylation. 
There has also been some progress in identifying elements in S-acylated substrate proteins 
that are required for their recognition by specific zDHHC enzymes. A proline residue 25 
amino acids downstream of the acylated cysteine-rich domain of SNAP25 is required for 
modification of this protein by zDHHC17 but not by zDHHC3 (77). In addition, a 
phenylalanine residue immediately upstream of the cysteine cluster is required for S-
acylation of the SNAP25b isoform by DHHC15 (75). Other work has shown that domains 
downstream from modified cysteines can also function to prevent promiscuous zDHHC-
substrate interactions. Full-length Vac8 was specifically S-acylated by Pfa3 in vitro but the 
isolated S-acylation domain was also modified by 4 other yeast zDHHC proteins (175). This 
observation emphasises the importance of considering changes in zDHHC-substrate 
specificity when analysing isolated protein domains or truncated proteins. 
Although a comprehensive analysis of zDHHC-dependent S-acylation has been undertaken 
in S. cerevisiae (212), we currently lack detailed information on the effects of knockdown of 
specific mammalian zDHHC enzymes on global S-acylation. One study examining cultured 
neural stem cells from the forebrains of zDHHC5 gene-trapped mice (which express 
zDHHC5 at around 5% of the levels present in cells from control mice) reported that S-
acylation of flotillin-2 was reduced by around 10-fold (139). In addition to flotillin-2, a group of 
approximately 20 other S-acylated proteins displayed decreased expression levels in 
zDHHC5 knockdown cells (139), possibly reflecting a requirement for S-acylation to stabilise 
these proteins. Interestingly, analysis of the brain S-acylated proteome from zDHHC17 
genetrap mice also showed that S-acylation of flotillin-1 and -2 was reduced by 36%, with a 
corresponding decrease in expression levels. A further 15 proteins were identified that had a 
24 
 
>10% loss in S-acylation (266). Further analysis of global S-acylation in zDHHC knock-out 
mice will provide invaluable data on the substrates of individual DHHC proteins. 
Although knowledge of how zDHHC-substrate specificity is encoded is rapidly evolving, 
there has been little work examining how specific zDHHC enzymes contribute to the lipid 
profile of S-acylated proteins (section II.iii). A recent study has shed some light on this issue 
by highlighting that different zDHHC enzymes incorporate and transfer different lipids with 
distinct efficiencies. 7KH DELOLW\ RI GLIIHUHQW µFRPSHWLQJ¶ OLSLGV WR EORFN 3H palmitate 
incorporation into zDHHC2 and zDHHC3, and subsequent transfer to substrate proteins was 
compared (112). Intriguingly, whereas only C14 and C16 lipids were efficient inhibitors of 
zDHHC3 autoacylation and substrate S-acylation, C14-C20 lipids all inhibited zDHHC2 to a 
similar extent. Further analysis confirmed that zDHHC2 transferred C18:0, C18:1 and C20:4 
lipids to a model substrate protein with broadly similar efficiencies, whereas zDHHC3 
strongly favoured C14/C16 lipids over C18/C20 lipids (112). It will be of particular interest in 
further work to delineate the sequence/structural basis for these differences in fatty acid 
specificity, and also to test whether zDHHC2 is responsible for the incorporation of stearic 
acid into the TMD of haemmaglutinin (129). 
 
IV.ii. S-acyl thioesterases 
In contrast to central role played by zDHHC enzymes in cellular S-acylation, far less is 
known about the enzymes and mechanisms that mediate protein deacylation. In fact, 
candidate thioesterases were identified many years prior to the realisation that zDHHC 
enzymes function as S-acyl transferases: Protein palmitoyl thioesterase 1 (PPT1) and PPT2 
are targeted to lysosomes and catalyse deacylation during protein degradation (23, 24, 93, 
235, 261), whereas acyl protein thioesterase 1 (APTI) is a cytoplasmic enzyme, implicated in 
dynamic S-acylation cycling of proteins (48). APT1 is active against proteins including 
eNOS, H/N-Ras, GD subunits, and BK potassium channels (48, 249, 279). A related protein, 
APT2 (~ 64% identical at amino acid level to APT1), has been reported to function as a 
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thioesterase against GAP43 and H-Ras but not BK potassium channels (249, 251). An 
additional protein, APT1-like thioesterase has activity against BK potassium channels (249). 
Research into the role of APT proteins in dynamic S-acylation has been supported by the 
recent development of thioesterase inhibitors. Palmostatin B, which is a broad spectrum 
inhibitor of APT proteins and other serine hydrolases, was employed to highlight the role of 
thioesterase enzymes (and specifically APT1) in dynamic S-acylation of Ras proteins (40). 
However, our knowledge of thioesterase regulation of dynamic S-acylation is still very much 
in its infancy. Indeed, recent studies using broad spectrum serine lipase inhibitors have 
revealed a significant subset of the large serine hydrolase family (that include the APTs and 
PPTs (12, 284)) are responsible for cellular depalmitoylation (157). This point is highlighted 
by a recent study that reported the blockade of deacylation of R7BP (a regulator of G protein 
signalling) by the general serine hydrolase inhibitors Palmostatin B and HDFP (115). This 
led to a redistribution of the protein from the plasma membrane onto endomembrane 
compartments (115). Intriguingly, these effects on R7BP deacylation and localisation were 
not replicated by either RNAi knockdown of APT1/APT2 or by specific inhibitors of these 
enzymes. Indeed, a combination of RNAi knockdown of APT1 and APT2 and treatment with 
specific inhibitors of both of these enzymes also failed to affect R7BP deacylation (115). 
These results thus suggest that there are likely to be many other serine hydrolase enzymes 
that function as deacylation enzymes, and which presumably add an additional layer of 
specificity into dynamic S-acylation of cellular proteins. 
 
IV.iii. MBOATs and Acylation of Secreted Proteins 
Although the major focus of this review is S-acylation, it is worthwhile noting that several 
secreted proteins are modified by different types of acylation that are critical for their 
signalling functions. Wnt, hedgehog and ghrelin are all acylated but, in contrast to substrates 
of the DHHC family, acylation occurs on the luminal side of intracellular membranes. The 
enzymes that mediate acylation of these secreted proteins belong to the MBOAT family of 
membrane-bound O-acyl transferases (21, 28). Wnt undergoes modification with palmitate 
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on a conserved cysteine residue, whereas the monounsaturated palmitoleate is added to a 
conserved serine residue. Porcupine mediates acylation of Wnt, at least with respect to 
palmitoleate attachment to serine (242). Palmitate is attached via an amide linkage to the N-
terminal cysteine of hedgehog (following signal peptide cleavage), and this modification is 
catalysed by hedgehog acyltransferase (193). Finally ghrelin O-acyltransferase transfers an 
O-octanoyl group onto a conserved serine residue of the peptide hormone ghrelin (275). The 
importance of these acyl modifications for the physiology of a diverse group of essential 
secreted proteins has led to an increasing interest in MBOATs as novel drug targets. In 
particular, there is a major interest in targeting the abnormal hedgehog signalling that is 
present in a high percentage of pancreatic and other cancer types via chemical inhibitors of 
Hhat (243). Palmitoylation and cholesterylation are essential for the biological activity of 
hedgehog, and recent work has reported the identification of novel small molecule inhibitors 
Hhat (195), which successfully block proliferation of pancreatic cancer cells (194). This 
example highlights the emerging clinical significance of MBOAT proteins and the potential to 
target these enzymes as novel drug targets in different disease states. 
 
IV.iv. Regulation of S-acylation 
Although S-acylation is a major regulator of cellular proteins and pathways, there is little 
information about how the dynamics of this process are regulated. S-acylation clearly is 
regulated as the acylation status of many proteins is modified in response to specific cues, 
such as PSD95, which exhibits changes in acylation that correlate with synaptic activity (38, 
52). Regulation of S-acylation might occur via effects on zDHHC enzymes, thioesterases, or 
direct effects on specific substrates. There is certainly constitutive regulation of specific 
zDHHC enzymes, for example, zDHHC9 function as an acyltransferase requires an 
obligatory co-factor, GCP16 (241). On the other hand, zDHHC17 has an intrinsic S-
acyltransferase activity that was recently suggested to be positively modulated by Huntingtin 
(106). A HTT-zDHHC17 complex immunoprecipitated from rat brain displayed 
acyltransferase activity towards recombinant SNAP25 (106). Depletion of HTT led to a 
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reduction of zDHHC17 S-acylation and a corresponding reduction in S-acylation of SNAP25 
and GluR1 (106). Interestingly, whereas a COS cell lysate containing wild-type HTT 
enhanced S-acylation of recombinant SNAP25 and PSD95 by zDHHC17, mutant HTT with a 
polyglutamine tract expansion did not stimulate S-acylation. 
There is also evidence that zDHHC enzymes are regulated by dynamic changes in their 
localisation. zDHHC2, which mediates activity-dependent S-acylation of PSD95, is regulated 
by dynamic changes in its localisation. This zDHHC enzymes enters a dynamic cycling 
pathway that traffics it between the plasma membrane and recycling endosomes (71). 
Blocking synaptic activity, which leads to enhanced S-acylation of PSD95 also modulates 
zDHHC2 trafficking (179), promoting its accumulation at the plasma membrane from where it 
can effectively modify PSD95 (62). 
Another potential mode of zDHHC2 regulation is via changes in its oligomeric state. Both 
zDHHC2 and zDHHC3 were shown to exhibit dimerization/oligomerisation, with the higher 
molecular weight forms potentially linked to a less active state of the enzymes (131). Future 
work should reveal if regulation of S-acyltransferase activity by self-association (and perhaps 
also hetero-multimerisation of zDHHC enzymes) might represent a mode of zDHHC 
regulation that is widespread through this enzyme family. 
An additional mode of regulation has been suggested to exist for zDHHC5. Growth factor 
withdrawal from neural stem cells led to a rapid proteasome-dependent degradation of 
zDHHC5 (139), which was inhibited by EGF and FGF. Thus, zDHHC5 activity is likely to be 
regulated via expression changes in response to specific extracellular cues (139),. 
A recent study also highlighted regulatory mechanisms occurring at the mRNA level. Micro-
RNAs have been shown to regulate the expression of both zDHHC enzymes and 
thioesterases. Whereas miR-138 regulates expression of APT1, leading to activation of GD13 
and spine shrinkage (228), miR-134 was shown to target zDHHC9 leading to a loss of 
plasma membrane targeting of H-Ras in GABAergic cortical interneurons (27). Interestingly, 
miR-138 and miR-134 appear to respond differently to neuronal activity, with miR-138 being 
repressed and miR-134 being activated by neuronal activ
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Regulation of substrate S-acylation can also occur independently of direct effects on zDHHC 
or APT enzymes. H-Ras typically displays an intracellular distribution across the Golgi and 
plasma membrane, with Golgi accumulation reflecting the continuous return of the protein to 
this compartment following depalmitoylation. Although the final 10 amino acids of H-Ras 
(containing both the farnesylated CAAX motif and palmitoylated cysteines) are sufficient for 
plasma membrane targeting (80), it was noted that this amino acid sequence displayed less 
Golgi localisation than the final 19 amino acids of H-Ras, when both sequences were fused 
to EGFP (6). This difference reflected a higher level of S-acylation of the 10 amino acid 
construct compared with the 19 amino acid domain, which was proposed to be due to a 
slower rate of deacylation (6). Pharmacological and mRNA knockdown experiments 
combined with site-directed mutagenesis of H-Ras suggested that binding of the cis-trans 
prolyl isomerase FKBP12 and cis-trans isomerisation of the glycine178-proline179 peptide 
bond (present in the 19 amino acid but not the 10 amino acid construct) was responsible for 
the enhanced deacylation rate of the longer H-Ras construct (6). A similar role for prolyl 
isomerases has been suggested in the regulation of Rac1 S-acylation, where 
pharmacological inhibition of prolyl isomerase activity (FK508) or mutation of proline 
residues adjacent to the acylation site increased incorporation of 3H palmitate into Rac1 
(176). One possibility to explain these effects is that prolyl isomerase action leads to an 
increased accessibility of the S-acylated cysteines to thioesterase enzymes; more work to 
explore how widespread the role of prolyl isomerisation is in the regulation of protein de-
acylation is clearly warranted. 
The S-acylation status of some proteins is also subject to regulation by different post-
translational modifications. In particular, there appears to be bidirectional interplay between 
S-acylation and phosphorylation for many proteins. In most cases the presence of one of 
these modifications is mutually exclusive or at least inhibitory to the other. PKA 
phosphorylation of the STREX variant of BK potassium channels interfered with S-acylation 
of adjacent cysteine residues, preventing membrane association of the C-terminal channel 
tail, and these effects were linked with PKA regulation of channel activity (111, 247). 
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Similarly, PKA phosphorylation of PDE10A2 inhibited S-acylation and membrane binding of 
this peripheral membrane protein (32). 
In addition to phosphorylation-DF\ODWLRQ LQWHUSOD\ WKHUH LV DOVR µFRPSHWLWLRQ¶ E\ GLIIHUHQW
cysteine modifications. Several studies have shown changes in protein S-acylation following 
cell treatment with nitric oxide donors (10, 13, 97). However as intracellular diffusion of NO is 
limited, physiologically-relevant protein nitrosylation (which occurs on cysteine residues) 
might be limited to substrates that are in close proximity to nitric oxide synthase. In this 
regard, a recent study highlighted mutually competitive effects of S-acylation and S-
nitrosylation on Cys-3 and Cys-5 of PSD95, a protein that binds directly to neuronal nitric 
oxide synthase (nNOS) (102). S-acylation of PSD95 on Cys3/Cys5 is essential for synaptic 
targeting of this protein and neurotransmitter receptor clustering (52). PSD-95 acts as a 
scaffold to couple Ca2+ influx through NMDA channels to activation of nNOS activity (18, 
218). Physiological production of NO was shown to lead to S-nitrosylation of Cys3/Cys5 and 
a decrease in PSD95 S-acylation and subsequent synaptic clustering. These effects were 
blocked by inhibition of nNOS (102).  Conversely, depletion of zDHHC8, which was reported 
to S-acylate PSD95 (171), led to an increase in PSD95 nitrosylation (102). This study thus 
highlights an intriguing reciprocal regulation of S-acylation and S-nitrosylation that is relevant 
to synaptic strength and plasticity. 
A recent study also highlighted a role for metabolic stress in the regulation of protein S-
acylation (22). Cardiac tissue from high fat and high sucrose fed mice or cultured arterial 
endothelial cells treated with high palmitate and high glucose were found to contain 
significantly reduced levels of S-acylated H-Ras and eNOS, and a corresponding reduction 
in plasma membrane targeting of these proteins. These effects on S-acylation were 
suggested to be caused by reactive oxygen species generated in endothelial cells in 
response to metabolic stress. Mass spectrometry analysis revealed that H-Ras from treated 
endothelial cells was S-glutathiolated on either Cys181 or Cys184 following metabolic stress, 
presumably competing or displacing S-acylation at these residues. 
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V. Tools to analyse S-acylation 
With the discovery of the zDHHC family of acyltransferases and recent advances in 
proteomic techniques to assay S-acylation, progress in the field has begun to accelerate.  
However, relative to other post-translational modifications, such as phosphorylation, the 
range of pharmacological, proteomic and genetic tools to investigate the functional role of S-
acylation remains somewhat limited.  Thus there is a real need, and opportunity, to develop 
improved tools to interrogate and manipulate S-acylation to develop our understanding of the 
physiological function of this PTM in health and disease. 
 
V.i. Assays of S-acylation 
$OWKRXJK QR µFRQVHQVXV¶ VHTXHQFH IRU 6-acylation exists a number of freely available 
prediction algorithms, such as CSS-palm v4.0 (203), provide an in silico platform to inform 
experimental approaches for candidate targets.  
Until relatively recently, radiolabelled palmitate (typically 3H but also 14C and 125I-labelled) 
incorporation (metabolic labelling) has been the mainstay for experimental validation of 
protein S-acylation over the last four decades. However, while this tool has been 
instrumental in studying the S-acylation of individual proteins it is not suitable for studying 
protein acylation in intact tissues, suffers from an inherent lack of sensitivity (detection can 
take months) and is not readily amenable to higher throughput proteomic analysis. To 
overcome many of these issues a range of alternative metabolic (lipid centric) labelling 
approaches and indirect assays of cysteine accessibility (cysteine centric) assays have been 
developed that are complimentary approaches. 
Lipid centric (metabolic) labelling assays: Metabolic labelling approaches are most suited to 
analysis of isolated cells, rather than tissues, but provide information on dynamic 
palmitoylation of proteins during the relatively short (~4h) labelling period and insight into the 
species of lipid bound to cysteine residues. Alternative labels have now been developed 
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including a variety of biorthagonal lipid probes (for reviews see (30, 83-85, 157, 250) such as 
the commercially available 17-octadecynoic acid (17-ODYA), that can be used in both 
fluoresecent imaging and protein purification assays. These labels are modified fatty acids, 
with chemical reactive groups, such as an alkyne or azide group, that are incorporated into 
S-acylated proteins E\WKH]'++&HQ]\PHV8VLQJ6WDXGLQJHUOLJDWLRQRUµFOLFN¶FKHPLVWU\D
range of fluorophores or protein capture reagents can then be conjugated to the reactive 
group. In particular, development of a family of Z-alkynyl fatty acid probes of different chain 
lengths (such as Alk-C16 and Alk-C18) have been exploited for proteomic profiling as well as 
single cell imaging with improved sensitivity (63) and have been used for proteomic profiling 
of S-acylated proteins in a variety of cell lines (see (31, 83, 156, 157, 278, 282).   In all these 
metabolic labelling assays it is essential to discriminate incorporation via S-acylation, 
through a labile thioester linkage to cysteine residues, rather than lipid incorporation via 
other mechanisms including: onto free N-terminal cysteines of proteins via an amide linkage 
(N-palmitoylation), addition via an oxyester linkage to a serine residue (O-palmitoylation and 
oleoylation) as well as myristate via amide linkages on glycine residues (84, 144, 219).  The 
most common method to discriminate S-acylation is to use hydroxylamine cleavage (at 
neutral pH) of the lipid: only lipids attached via a thioester bond (s-acylation) are cleaved.   
Cysteine centric (cysteine accessibility) assays: Acyl-biotin exchange (ABE) and resin-
assisted capture (Acyl-RAC):  To circumvent the limitations of the labelling approach, which 
requires metabolic incorporation of lipid typically to isolated cells, a number of related 
approaches have been developed that exploit the exposure of a reactive cysteine following 
hydroxylamine cleavage (at neutral pH) of the cysteine-acyl thioester linkage.  The newly 
exposed cysteine thiol can then react with cysteine-reactive groups (such as biotin-BMCC or 
biotin-HPDP used in the ABE approach (43-45, 265)) or thiopropyl sepharose (used in Acyl-
RAC (56)) typically to allow purification of S-acylated proteins. While it must be remembered 
that these assays do not determine the nature of the bound lipid, rather the presence of a 
cysteine with a cleavable thioester linkage, these approaches have been exploited to 
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GHWHUPLQHWKHµS-acylated proteRPH¶LQDQXPEHURIVSHFLHVDQGWLVVXHV(118, 122, 156, 162, 
265, 266, 268, 276, 282). These methods have also been adapted to allow more quantitative 
labelling in vivo (266) and have been reported to improve detection of high molecular weight 
proteins. Cysteine accessibility approaches determine the net amount of pre-existing S-
acylated proteins; however, caution is required to eliminate false positives, in particular it is 
necessary to fully block all reactive cysteines prior to hydroxylamine cleavage.   
In conjunction with site±directed mutagenesis of candidate S-acylated cysteine residues, the 
lipid- and cysteine- have provided substantial insight into the diversity of proteins that are S-
acylated. These approaches can be refined to determine peptides that encompass the S-
acylated cysteine. However, mass spectrometry±based approaches to identify the native 
lipid specifically bound to S-acylated cysteines remain a significant challenge, in particularly 
for low abundance proteins such as membrane proteins (114, 128, 129, 158, 234). Similarly, 
tools widely available for other PTMs such as phospho-specific antibodies, to allow assay in 
tissue sections for example, are not available in the S-acylation field. A recent novel 
approach has been the exploitation of an intrabody that recognises the S-acylation induced 
conformational changes in the scaffolding protein PSD-95, rather than S-acylation per se 
and this can be used as an indirect measure of S-acylation in cells (62). 
 
V.ii. Pharmacological manipulation of S-acylation 
Although significant advances have been made with respect to assays for detecting S-
acylated proteins, the pharmacological toolkit to manipulate S-acylation in vitro and in vivo 
remains very limited, compared to many other PTMs. For example, the palmitate analogue 
2- bromopalmitate (2-BP), that is very widely used for functional analysis of S-acylation, 
should be used with caution, even though it remains our best pharmacological inhibitor of 
zDHHCs (207, 289). Unfortunately, 2-BP does not show selectivity toward specific zDHHC 
proteins (113); also inhibits acylthioesterases (192); is a non-selective inhibitor of lipid 
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metabolism and many proteins with a membrane accessible cysteine residue (see for 
example, (39)) and; at high concentrations has many pleiotropic effects on cells, including 
cytotoxicity (207). Other, less widely used, lipid inhibitors include cerulenin, which affects 
many aspects of lipid metabolism, and tunicamycin that also inhibits N-linked glycosylation 
(207). Although some non-lipid inhibitors have been developed, these are not widely used 
(46, 113) and there are currently no known activators of zDHHCs or compounds that inhibit 
specific zDHHCs.  In the last few years, a number of inhibitors for the acylthioesterases 
APT1 and APT2 have been developed (3, 12, 40). However, several of these compounds, 
such as palmostatin B, are active against several members of the larger serine hydrolase 
family. Clearly, the development of novel S-acylation inhibitors and activators that display 
both specificity and zDHHC selectivity would represent a substantial advance for 
investigation of S-acylation. 
 
V.iii. Genetic tools and models 
Since the seminal discovery of the mammalian enzymes that control S-acylation (61) both 
overexpression and knockdown strategies have been developed to interrogate S-acylation. 
Overexpression studies have predominantly exploited expression of candidate zDHHCs,and 
WKHLUFDWDO\WLFDOO\ µGHDG¶'++6PXWDQWV LQKHWHURORJRXVH[SUHVVLRQRUQDWLYHV\VWHPVDQG
analyzed increases in 3H-palmitate incorporation to define zDHHCs that may S-acylate 
specific proteins. Although this is a powerful approach, caution is required as overexpression 
can result in S-acylation of cysteine residue(s) that are not endogenously S-acylated in 
native cells (248). Increasingly, knockdown of endogenous zDHHCs using siRNA, and 
related approaches, is beginning to reveal the identity of zDHHCs that S-acylate native 
proteins. However, relatively few studies have taken a systematic knockdown approach to 
identify zDHHCs (for examples see (132, 248, 249)). Furthermore, as some zDHHCs and 
APTs are themselves palmitoylated, the functional effect of overexpressing or knocking 
down individual zDHHCs on the localization and activity of other zDHHCs, and APTs, must 
also be carefully determined. For example, siRNA-mediated knockdown of zDHHC 5, 7 or 17 
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in HEK293 cells paradoxically results in an upregulation of zDHHC23 mRNA expression 
(249). An important, caveat of many of these approaches is the lack of tools to analyse 
native zDHHC protein expression due to the lack of high quality antibodies for western 
blotting and immunocytochemistry for most zDHHCs. Increasingly, a variety of mouse Gene-
trap and global as well as conditional knockout models for some zDHHCs are becoming 
available although full phenotypic analysis is limited in most cases (see section III.iv).  
Similar overexpression and knockdown approaches have also started to be exploited to 
interrogate APT function. 
 
VI. Diversity of proteins regulated by S-acylation 
As highlighted in the previous sections, an eclectic array of proteins from viruses to man 
(Figure 5), have been reported to be S-DF\ODWHGDQGWKHµFDWDORJXH¶LVHYHUH[SDQGLQJZLWK
the increasing number of S-acylation (palmitoyl) proteomic screens (30, 83, 108, 118, 122, 
139, 155-157, 162, 265, 266, 268, 276, 278, 282). Furthermore, available predictive tools 
suggest a large proportion of the cellular proteome may be S-acylated.  
In this section we highlight a number of cellular pathways and protein families in eukaryotes 
that have been shown to be S-acylated. While not exhaustive, we attempt to emphasise the 
diverse array of physiological processes and mechanisms that may be regulated by S-
acylation to reveal both the opportunities and challenges for investigators entering the field. 
VI.i Membrane receptors and signalling 
Multiple types of cellular signalling receptors are now known to be regulated by S-acylation, 
from classical G-protein coupled receptors to the more recent insights into membrane 
receptors for steroid hormones. 
VI.i.a G-protein coupled receptor (GPCR) signalling 
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6LQFHWKHµSURWRW\SLFDO¶*-protein coupled receptor, rhodopsin, was shown to be S-acylated 
more than 30 years ago (180, 185)  the large majority of GPCRs examined have been 
shown to be S-acylated at typically one, two or three residues in the C-terminal cytoplasmic 
tail following the last transmembrane domain (for reviews see (37, 201). Notable exceptions 
include the GnRH receptor and a Thromboxane A2 splice variant that lack the conserved 
cysteine residues.   However, although the S-acylated cysteines are conserved, and S-
DF\ODWLRQ KDV EHHQ SURSRVHG WR JHQHUDWH DGGLWLRQDO µORRSV¶ LQ WKH &-terminus for many 
GPCRs, the effect of S-acylation on particular GPCRs cannot be easily predicted and the 
reported functional effects are as diverse as the family of GPCRs and their agonists. Indeed. 
In the E1-adrenoreceptor different sites of S-acylation in the C-terminal tail turn over at 
different rates and control distinct functions (294). 
S-acylation has been reported to control tertiary structure including by controlling receptor 
dimerization in E2-adrenergic and P-opioid GPCRs (36, 290). Furthermore, recent insights 
from mice lacking S-acylated rhodopsin, via knock-in mutations of the S-acylated cysteines, 
reveals an important structural role for S-acylation by controlling the stability of rhodopsin, 
rather than its signalling via G-proteins, in vivo (153). S-acylation is required for correct 
PDWXUDWLRQLQWKH(5VXEVHTXHQWWUDIILFNLQJWRWKHSODVPDPHPEUDQHDQGWDUJHWLQJWRµOLSLG
UDIW¶GRPDLQVIor several, but not all, GPCRs. Moreover, efficient coupling between agonist 
binding and G-protein activation is reported for several GPCRs, including adrenalin 
stimulation of the E2-adrenoreceptor through Gs proteins to activate adenylate cyclase. 
Here, the S-acylation deficient E2-adrenergic receptor C341G mutant is less efficient at 
stimulating adenylate cyclase activity than the wild type protein (181), an effect due to the 
C341G mutant being hyperphosphorylated by PKA and thus resembling a desensitised 
receptor, again demonstrating important cross-talk between distinct signalling pathways 
(169, 170). Moreover, for some GPCRs S-acylation can act as a switch to allow differential 
coupling with different effectors. In the V2 vasopressin receptor, S-acylation is required for 
stimulation of the MAPK pathway following receptor internalisation (29) and in the endothelin 
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A receptor is required for coupling through Gq to regulate phospholipase C (103).  In both 
cases, S-acylation did not affect coupling to adenylate cyclase through Gs. In contrast, de-
acylation of the proteinase-activated receptor 2 promotes activation of the ERK pathway 
highlight diverse effects of S-acylation of GPCR coupling (17). Agonists can also modify the 
S-acylation status of GPCRs (148) and S-acylation controls receptor desensitization and 
internalisation. 
Recent studies reveal how S-acylation-dependent control of GPCR signalling is potentially 
even more complex as both G-proteins, multiple effectors as well as a range of molecules 
that regulate GPCR signalling may also be S-acylated.  
The Galpha subunits of heterotrimeric G-proteins themselves are S-acylated and S-acylation 
is required for plasma membrane localisation (37, 201). For example, zDHHC3 & 7 
overexpression robustly S-acylated Gq, Gs and Gi subunits expressed in HEK293 cells. S-
acylation controls Gq shuttling between the Golgi, where Gq is S-acylated, and the plasma 
membrane with inhibition of Gq S-acylation blocking D1-adrenergic signalling through Gq 
(255).  
Several members of two important protein families that control GPCR function are also S-
acylated: members of the GPCR kinase (GRK) family important in the control of GPCR 
desensitization and the regulator of G-protein signalling (RGS) proteins that regulate the 
activity of G-proteins themselves, by accelerating GTP hydrolysis, and terminating Gi/o 
signalling by speeding Gi/o deactivation at the plasma membrane  (37, 201).. As examples, 
GRK6 is S-acylated at a cluster of three cysteine residues in the C-terminus that promotes 
its targeting to the plasma membrane and stimulates kinase activity thus enhancing GPCR 
desensitization (117, 238). Several members of the RGS family are S-acylated at the N-
terminus however the role of S-acylation differs between family members with both positive 
and negative effects on GTPase activity reported. However, S-acylation also indirectly 
regulates some members of the RGS family. For example, membrane targeting of RGS-R7 
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is controlled through assembly with an S-acylated R7 binding protein (R7-BP), that also acts 
as an allosteric activator, to control G-protein coupled potassium channel activity (115).  In 
neurones, R7-BP S-acylation is dynamically controlled by zDHHC2, furthermore R7-BP S-
acylation is increased upon activation of Gi-linked GPCRs through slowing of de-acylation 
R7-BP revealing an intimate interplay between G-protein signalling and control of G-protein 
activity via S-acylation of R7-BP (116). In addition, several downstream effectors of G-
proteins, including some members of the Rho guanine nucleotide exchange factor (RhoGEF) 
family, are also S-acylated.  For p63RhoGEF, a Gq regulated RhoGEF, S-acylation of a 
conserved cluster of cysteine residues (C23, 25 & 26) in the N-terminal domain target 
p63RhoGEF to the plasma membrane. This constitutive targeting (unlike most other 
RhoGEFs that are sequestered in the cytosol) to the plasma membrane promotes basal 
activity of p63RhoGEF as mutation of the S-acylated cysteines reduces activity and re-
localises it to the cytoplasm (9). 
Clearly defining the network of S-acylation within the GPCR-signalling complex will remain a 
significant, yet important challenge, to identify key principles and nodes that are critical for 
signalling by this very important class of cell-surface receptors.  
 
VI.i.ii Membrane receptors for steroid hormones 
7KHµFODVVLFDO¶VWHURLGUHceptors exist predominantly in the nucleus where they mediate both 
ligand-dependent and independent control of gene transcription. However, for many steroid 
receptors, including the oestrogen (ERD, progesterone PR) and androgen (AR) receptors, a 
significant fraction of the receptor may be localised at the plasma membrane where they can 
mediate non-genomic steroid signalling cascades. The membrane targeted fraction of these 
receptors are S-acylated, at a single cysteine residue, in the ligand binding domain of the 
receptor (191) by zDHHCs 7 and 21 (189). S-acylation is required for both membrane 
targeting as well as the rapid, non-genomic effects of these steroids.  For example, site 
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directed mutation of the S-acylated cysteine to alanine in the ERDreceptor, prevent 
ERD
that controls non-genomic regulation of the MAPK/ERK and PI3Kinase/AKT signalling 
pathways.  In contrast, de-acylation of ERD  
ERDdegradation and abrogates oestrogen induced gene transcription revealing cross-talk 
between the non-genomic and genomic mechanism of action of oestrogen (130). Recent 
analysis of mice with knock-in mutations of the S-acylated cysteine in ERD, to alanine, 
reveal discrete developmental and physiological functions controlled via the membrane (S-
acylated) ERD receptors including in the female reproductive, endocrine and vascular 
systems (4, 190). The in vivo roles of PR and AR S-acylation remain to be fully explored. 
Furthermore, whether other steroid receptors, that also have the conserved cysteine in the 
ligand binding domain, and have been reported to have membrane mediated effects (e.g 
receptors for cortisol) are also regulated by S-acylation remains to be examined.  
S-acylation is also critical for the rapid non-genomic effects of thyroid hormone (TH) 
signalling via a novel membrane TH receptor, that lacks the conserved cysteine residue 
seen in the ER and other steroid receptors above (119). In this case, the membrane receptor 
is generated by translational initiation from an internal methionine (M150) of the ligand-
activated transcription factor receptor TRD. This produces a receptor (p30 TRD1) that is 
unable to stimulate transcriptional but is instead targeted to caveolae through S-acylation of 
two cysteine residues C254 and C255 in osteoblasts. S-acylation of p30 TRD1 is essential 
for the non-genomic actions of thyroid hormone as signalling through the NO/cGMP 
signalling cascade to ultimately control extracellular signal related kinase (ERK) and Akt was 
abolished in mutants deficient for S-acylation. Thus this novel receptor is required for the 
rapid non-genomic signalling of thyroid hormone and the control of cell survival and 
proliferation.  
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VI.ii Membrane and vesicle trafficking 
Vesicle trafficking, exocytosis and endocytosis are fundamental mechanisms for controlling 
bulk trafficking of proteins in cells as well as the control of intercellular communication 
through the release of hormones and neurotransmitters. S-acylated proteins are involved in 
both vesicle translocation as well as fusion/retrieval from membranes.  
VI.ii.a Vesicle trafficking and exocytosis 
The fusion of vesicles to their target membrane requires assembly of SNARE complex 
proteins to promote membrane fusion. In neurones multiple components of the vesicle fusion 
machinery are S-acylated including both the pre-synaptic membrane SNARE proteins 
syntaxin and SNAP25, the vesicle protein synaptobrevin (VAMP2) as well as the calcium 
sensor for fusion Synaptotagmin 1 (see (122, 200). S-acylation controls multiple aspects of 
protein sorting and localisation to membrane microdomains for these proteins.  
Multiple members of the syntaxin family, including both neuronal (e.g syntaxin 1) and non-
neuronal (e.g syntaxin 11) expressed syntaxins, have been reported to be S-acylated 
although in most cases the functional role is very poorly understood.  The endosomal 
syntaxin 7, S-acylated at a cysteine residue (C239) juxtaposed to its single transmembrane 
domain is important for trafficking between endosomal and plasma membranes as its S-
acylation deficient mutant is trapped on the plasma membrane (90).  Recent analysis of the 
atypical syntaxin, syntaxin 11, that lacks a transmembrane domain, reveals an important role 
for S-acylation in membrane targeting, and localisation of syntaxin11 to the immunological 
synapse in natural killer (NK) cells and association of loss of S-acylation dependent targeting 
in familial hemophagocytic lymphohistiocytosis type 4 (FHL-4) (92).  Syntaxin 11 is widely 
expressed in immune cells and in NK cells is required for secretory lysosome exocytosis, 
required for elimination of pathogens or tumor cells a function severely abrogated in FHL-4.  
In NK cells, Syntaxin 11 is S-acylated at a cluster of cysteine residues at the C-terminus of 
the protein, a region that is lost due to frameshift mutations (e.g Q286X) in patients with 
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FHL-4. Syntaxin that is not S-acylated does not bind membranes resulting in disruption of its 
interaction with the Sec-1/munc18-like protein Munc18-2 at the immunological synapse in 
activated NK cells.  
SNAP25, and the related non-neuronal protein SNAP23, are both peripheral membrane 
proteins that interact with membranes through S-acylation of multiple cysteines in cysteine 
rich domains of the proteins. SNAP25, plays a role in both synaptic and endosomal 
membrane fusion events and its targeting to membranes is controlled by S-acylation of a 
cluster of four cysteine residues C85, C88, C90 & C92, predominantly by zDHHCs 3, 7 and 
17 in the Golgi network (75). Importantly, the number of cysteine residues of SNAP25 that 
are S-acylated appears to act as a code to specify the precise sub cellular distribution in the 
recycling pathway between recycling endosomes, the trans Golgi network (TGN) and the 
plasma membrane (73). For example, in neuroendocrine PC12 cells mutation of any 
individual S-acylated cysteine to leucine enhanced SNAP25 localisation at recycling 
endosomes and the TGN although mutation of either C88 or C90. had the greatest effect. As 
SNAP25 S-acylation is dynamic this suggests that controlling the extent of SNAP-25 S-
acylation is a key determinant in defining its localisation and supports multiple lines of 
evidence that S-acylation is not a simple membrane anchor. Moreover, the number of S-
acylated cysteines in both SNAP25 and SNAP23 are important determinants in the role of 
these proteins to support secretion in neuroendocrine cells.  For example, engineering an 
additional cysteine into SNAP25 (to have 5 rather than 4 S-acylated cysteines) results in 
reduced stimulated secretion compared to wild-type whereas in a converse experiment 
deleting a cysteine in SNAP 23 (so it has 4 rather than the normal 5) results in enhanced 
secretion (214).   
Cysteine string protein D (CSPD) is a ubiquitously expressed DnaJ chaperone protein that 
regulates secretory vesicle dynamics likely by stabilising multiple synaptic proteins including 
SNAP25, and represents one of the most heavily S-acylated proteins per mole. S-acylation 
of CSP occurs on multiple residues in a core cysteine-rich domain. Mutations within this 
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cysteine rich domain (L115R or 'L116), recently shown to cause the neurodegenerative 
disorder adult-onset neuronal ceroid lipofuscinosis, result in aggregation of CSPD (76). The 
mutations mistarget CSPD resulting in aggregates of mutant CSPD that are membrane 
bound with incorporated palmitate. Although oligomerization of mutant CSPD can also occur 
in the absence of S-acylation (286) chemical de-acylation solubilises the aggregates in cell 
lines and in post-mortem brains of patients suggesting that CSPD S-acylation of these 
mutants is a major driver of the onset of this disease and aggregate formation (76).  
Synaptobrevin is S-acylated at a single cysteine residue within its transmembrane domain 
and although the functional role of S-acylation is not known S-acylation of synaptobrevin 
may be developmentally regulated as synaptic vesicles prepared from adult rat brain 
efficiently incorporated 3H-palmitate whereas vesicles isolated from embryonic brains did not 
(259).  
Synaptotagmins represent a large family of calcium-sensors for vesicle fusion with a single 
transmembrane domain. The major neuronal isoform synaptotagmin 1 is S-acylated at 
multiple cysteine residues at the boundary between the transmembrane domain and 
cytosolic domain. In neurones, synaptotagmin1 S-acylation is enhanced by inhibiting 
synaptic activity and mutation of the S-acylated cysteines results in enhanced surface 
expression and diffuse localisation rather than punctate localisation to presynaptic 
membranes (121) suggesting a role of S-acylation in clustering and stability at the plasma 
membrane. Synaptotagmin VII (Syt VII) is an example of a more broadly expressed 
synaptotagmin that is localised to lysozomes, as well as other compartments, in a variety of 
cells including macrophages.  In bone marrow macrophages from SytVII knockout mice, 
phagocytosis, which is dependent upon lysosomal membrane delivery to the cell surface, is 
disrupted and this could be restored by overexpression of wild-type but not S-acylation 
deficient mutants (55). Wild-type SytVII was correctly targeted to lysozomes where it is 
assembled in clusters with the tetraspanin CD63 whereas S-acylation deficient SytVII 
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mutants localised at the Golgi and did not assemble with CD63.  S-acylation dependent 
assembly of SytVII with CD63 is required at the level of the Golgi to allow SytVII to traffic to 
lysozomes directed by the lysosomal targeting motifs of CD63. 
VI.ii.b Microtubule-mediated trafficking 
S-acylation has also been implicated in the control of dynein-dependent motor protein 
function that controls multiple aspects of cellular function: from long range transport of cargo 
vesicles to mitosis. The anterograde motor protein dynein is an important microtubule 
associated motor protein and is regulated by a protein complex composed of the proteins 
LIS1 and the evolutionary conserved NUDE proteins Ndel1 and Nde1.  Both Ndel1 and 
Nde1 are S-acylated, with zDHHCs 2, 3 and 7 the major candidates, most likely at multiple 
sites although in both proteins conserved C273 in the Ndel1 dynein binding domain appears 
to be the major residue (227). However the effect of S-acylation is divergent between Ndel1 
and its paralog Nde1.  For Ndel1, S-acylation reduces the ability of Ndel1 to interact with 
cytoplasmic dynein that results in reduced dynein activity and hence disruption of a number 
of key dynein±dependent processes including maintenance of the Golgi apparatus, 
trafficking from ER to Golgi and long range vesicular trafficking in neurites. In contrast, S-
acylation of Nde1 does not significantly affect dynein activity or function.  Importantly, S-
acylation of Ndel1 is involved in neuronal migration both in vivo and in vitro. In vivo (using in 
utero electroporation), expression of a dominant negative mutant of zDHHC7, or the C273S 
Ndel1 mutant, resulted in reduced neuronal migration in the developing cortex (227).  
VI.ii.c Massive endocytosis 
Endocytosis of transmembrane proteins may occur through multiple mechanisms including 
WKH µFODVVLFDO¶ FODWKULQ-dependent pathway as well as clathrin-independent pathway. For a 
variety of proteins, clathrin-independent endocytosis may occur through S-acylation 
dependent partitioning of the protein into cholesterol and sphingolipid rich lipid raft 
microdomains. Recently, a mechanism (massive endocytosis, MEND) that promotes large 
scale (e.g up to 50%) endocytosis of such ordered plasma membranes has been described 
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to be, in part, triggered by S-acylation in cardiac myocytes and other cells (100, 143). MEND 
is activated in cardiac cells upon calcium influx or insults that that result in elevations in acyl-
CoA in the cytoplasm, along with activation of PKC.  These conditions are manifest following 
re-oxygenation of cardiac cells following acute ischaemic events, for example during heart 
attacks.  Thus reoxygenation of anoxic cardiac myocytes initates MEND, a process that is 
proposed to result from formation of permeability transition pores in the mitochondrial 
membrane resulting in release of Coenzyme A into the cytoplasm. The release of Coenzyme 
A results in a rapid increase in acyl-CoA providing an unlimited supply of acyl-CoA for 
zDHHC enzymes with consequent enhanced S-acylation of multiple membrane proteins  
including phospholemman and flotillin.  The increased S-acylation of such proteins is then 
hypothesised to result in clustering and association of these proteins in ordered lipid raft 
domains and thus promoting endocytosis.  Although the precise mechanisms that result in 
such massive membrane internalisation remain to be established, knockdown of zDHHC5 in 
cardiac myocytes (via siRNA or using myocytes from a mouse with a hypomorphic allele of 
zDHHC5 largely prevented MEND (143). Furthermore, hypomorphic zDHHC5 mice retained 
ventricular function following ischaemia suggesting that zDHHC5 mediated S-acylation is a 
critical check-point in MEND and reperfusion injury in the heart. 
 
VI.iii Ion channels and Transporters 
S-acylation has been reported to control a diverse array of ion channels as well as 
transporters that move ions, lipids or other solutes across membranes. S-acylation is 
important for controlling both channel/transporter activity as well as trafficking to target 
membranes, effects that are mediated by S-acylation of the pore/transporter subunits or 
associated regulatory/accessory subunits.  Recent extensive reviews have highlighted the 
diversity of ion channels and mechanisms/properties regulated by S-acylation and thus here 
we focus on a few select examples to illustrate key points (225, 226, 246).  
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VI.iii.a Ion channels 
Since the discovery of the first S-acylated ion channels more than 25 years ago (220, 239) 
more than 50 different ion channel subunits have been reported to be S-acylated (for 
reviews see (225, 226, 246). S-acylation has been reported to control all aspects of the ion 
channel life cycle from assembly, trafficking, kinetics and regulation by other PTMs at the 
destination membrane to degradation and sensitivity to toxins and pharmacological agents. 
Importantly, ion channels have been shown to be regulated by S-acylation of pore forming 
subunits as well as an array of regulatory subunits that control channel trafficking and 
function.  To illustrate some of the key features and diverse roles S-acylation plays in ion 
channel function two exemplars from the ligand-gated and voltage gated ion channel families 
will be discussed: the glutamate activated 
D­amino­3­hydroxyl­5­methyl­4­isoxazole­propionate (AMPA) receptors and large 
conductance calcium- and voltage activated potassium (BK) channels, respectively.  
AMPA receptors (AMPAR) are critical determinants of glutamatergic signalling in central 
synapses and the control of AMPAR surface expression and function key to mechanisms of 
synaptic plasticity. The pore forming subunits, encoded by four genes Glu1-4, are S-acylated 
at two distinct sites.  S-acylation of a single cysteine residue in Glu1, that is located adjacent 
to a cytosolic hydrophobic segment between two transmembrane domains, promotes 
retention of AMPAR at the Golgi apparatus (86). In contrast, S-acylation of a cluster of 
cysteine residues in the cytosolic C-terminus of GluA1, just downstream of the last 
transmembrane domain, blocks PKC-mediated phosphorylation of GluA1 likely through a 
mechanism of steric hindrance (142).  This S-acylation-dependent regulation of PKC 
phosphorylation prevents GluA1 binding to its cytoskeletal adapter protein 4.1N and 
reducing AMPAR insertion into the plasma membrane.  The functional diverse effects of S-
acylation at two distinct site within the same pore-forming subunit are also observed for BK 
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channels.  The pore forming subunit of BK channels encoded by the single gene KCNMA1, 
is again S-acylated at two sites. Firstly, S-acylation of a cluster of cysteine residues (C53 & 
56) in a cytosolic loop between the first two transmembrane domains is required for efficient 
trafficking of the BK channel from the ER to Golgi and subsequently the cell surface (110, 
249). In contrast, S-acylation of a BK channel C-terminal splice variant (STREX) in a 
cysteine-rich cytosolic domain acts as a switch to specify STREX BK channel regulation by 
AGC-family protein kinases (247). Channels S-acylated in the STREX insert are inhibited by 
PKA-dependent protein phosphorylation but are insensitive to PKC regulation. In contrast, 
de-acylation of the STREX insert switches the channel from being inhibited by PKA to being 
inhibited by PKC (292), a mechanism proposed to involve accessibility of the PKC 
phosphorylation site only when the STREX domain is not S-acylated and hence dissociated 
from the plasma membrane. 
Importantly, in both AMPAR and BK channels the distinct sites of S-acylation appear to be 
under control of distinct members of the zDHHC family. How, zDHHCs discriminate between 
these distinct sites is as yet unknown.  
While S-acylation of the pore-forming subunits can have differential effects, the diversity of 
effects of S-acylation on channel function is also illustrated in these two channel types 
through S-acylation of distinct regulatory subunits and adapter proteins.  For example, S-
acylation of the AMPAR interacting protein PICK1, retains endocytosed AMPAR in 
intracellular compartments and thus contributes to long-term depression of glutamatergic 
synapses (245). Another AMPAR interacting protein Grip1b, that is also S-acylated by 
zDHHC 5 & 8 as for PICK1, accelerates local recycling of AMPAR to the plasma membrane 
in dendritic spines through interaction of S-acylated Grip1b with dendritic trafficking vesicles 
(244). Moreover, S-acylation of another AMPAR interacting adapter protein, PSD-95, in 
dendritic spines controls AMPAR clustering at the postsynaptic membrane (62).  The role of 
regulatory subunits in BK channels is likely to be as complex. For example, S-acylation of 
the regulatory E4-subunit, at a single juxtatransmebrane cysteine residue C193, is required 
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for the up-regulation of BK channel surface expression when E4-subunits are expressed with 
pore-forming subunits in neurones through control of ER exit. Intriguingly, this S-acylation 
dependent mechanism is only manifest with specific C-terminal splice variants of the pore-
forming subunit illustrating how surface expression may be finely and differentially tuned in 
different cell types (33). Such mechanisms likely contribute to the diverse roles that BK 
channels play in an eclectic range of physiological process: from control of neuronal 
excitability to endocrine, vascular and renal function.  
A recent intriguing study has also revealed a role for S-acylation in controlling trafficking of 
the cystic fibrosis transmembrane conductance regulator (CFTR). CFTR is a chloride and 
bicarbonate channel that is central to the pathogenesis of the enhanced mucus lining the 
lung in cystic fibrosis (159).  Several disease causing mutations of CFTR, including F508del, 
result in reduced, but not abolished, trafficking to the cell surface as  deletion of Phe508 
results in misfolded CFTR that is recognised for degradation by ER-associated degradation 
(ERAD). Rescue of F508del surface expression by small molecule correctors allows 
functional rescue as the F508del mutant retains partial transport activity at the plasma 
membrane. Both wild-type CFTR and the F508del mutant are S-acylated, with zDHHCs 3 
and 7 likely candidates, resulting in increased steady-state levels of the protein. S-acylation 
promotes biogenesis of core-glycosylated CFTR promoting trafficking of both wild-type and 
F508del mutant channels from the ER to the Golgi where they are sequestered.  It is likely 
that additional de-acylation steps are required for efficient transport to the cell surface from 
the Golgi. However, manipulation of mutant CFTR S-acylation, in conjunction with 
established small molecule enhancers of trafficking/function may provide a new strategy for 
treatment of this disabling disorder.  
VI.iii.b Ion, solute and lipid transporters 
A wide variety of neurotransmitter, ion, solute and lipid transporters have also now been 
revealed to be regulated by S-acylation and below we highlight some key examples. 
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Dopamine transport is essential in controlling synaptic levels of dopamine and consequent 
regulation of a wide range of nervous system functions including in emotion, reward and 
motor pathways. The efficiency of active reuptake of dopamine from the extracellular space, 
back into presynaptic nerve terminals in central synapses, by the dopamine transporter 
(DAT) is enhanced by S-acylation of the transporter at at least two sites, including a cysteine 
(C580) at the intracellular end of transmembrane 12 (57).   Acute pharmacological inhibition 
of S-acylation, using 2-BP, reduced transporter V0.5max in synaptosomes without affecting 
transporter expression or surface membrane expression. However chronic inhibition, or site-
directed mutagenesis of C580 to serine, resulted in enhanced receptor degradation and 
enhanced protein kinase C-dependent down-regulation of transporter function (57).   
Dopamine transporters are targets for both therapeutic drugs and drugs of abuse, and thus 
both short and long term effects of S-acylation may have major impacts on dopamine 
neurotransmission and dopaminergic disorders. However, whether DAT S-acylation is 
compromised in disease states, such as Parkinson;s and schizophrenia, or can be targeted 
to enhance dopamine transport remains to be examined.  
The ATP-binding cassette transporters ABCA1 and ABCG1 are both found at the plasma 
membrane, where they transport cholesterol out of the cell to apoliporotein A1 and 
subsequent formation of high density lipoprotein (LDL) (79, 231).  In both cases S-acylation 
is required for efficient trafficking of the transporter from the ER to plasma membrane thus 
transporter deacylation results in reduced cholesterol export in a variety of cell types. ABCA1 
is S-acylated on 5 cysteine residues, with two residues within the intracellular N-terminus 
(C3 and C23) and a dicysteine motif (C1110 and C1111) in the large intracellular linker 
between transmembrane domains 6 and 7. Mutation of any cysteine has similar effects on 
ABCA1 surface expression and cholesterol efflux suggesting the cysteine residues play 
similar functions (231). ABCA1 is S-acylated by multiple zDHHCs although zDHHC8 shows 
the most robust S-acylation in overexpression assays. Moreover, zDHHC8 overexpression 
up regulates ABCA1 transporter function (231). In contrast, ABCG1 is S-acylated at 5 
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residues although residue C311 appears to be primarily responsible for controlling trafficking 
and cholesterol efflux (79). This again highlights that cysteines at distinct locations with 
proteins can display similar or distinct functions. The apolipiporoteins are also  S-acylated 
and S-acylation of ApoB at C1085 is important for its intracellular sorting and formation of 
LDL (288). Whether dysregulation of ABC transporter S-acylation is associated with 
disruption of cholesterol transport in a range of disorders including artherosclerosis, Macula 
degeneration and some cancers remains to be determined.  
The glucose transporters Glut1 and Glut4 are both reported to be S-acylated and the level of 
S-acylation changes in diet-induced models of hyperglycaemia or obesity respectively (198, 
205).  However, although the functional role of Glut1 or 4 S-acylation is not fully understood, 
S-acylation plays an important role in controlling insulin dependent Glut4 translocation to the 
plasma membrane via indirect mechanisms.  Several components important for Glut4 
vesicle trafficking, including cytoplasmic linker protein 170-related 59 kDa (ClipR59), 
involved in regulating glucose homeostasis and peripheral insulin sensitivity, are S-acylated 
in adipocytes. ClipR-59, acts as a scaffold to drive phosphorylation of the Rab GTPase 
activating protein AS160 (that is also S-acylated Ren:2013fa) by the protein kinase Akt to 
drive insulin-dependent recruitment of Glut4 to the plasma membrane. S-acylation of two 
cysteine residues (C534 and C535) of ClipR-59 promotes membrane interaction and allows 
ClipR-59 to recruit the kinase Akt to the plasma membrane (206).  ClipR-59 assembles with, 
and is predominantly S-acylated by, zDHHC17. Knockdown of zDHHC17 prevents ClipR-59 
and Akt recruitment to the plasma membrane and impairs insulin-induced Glut4 translocation 
to the plasma membrane. As multiple components required for Glut 4 trafficking, including 
Glut 4 itself, are S-acylated this PTM may play a complex role in Glut4 translocation and 
insulin signalling.  
Phospholemman (FXYD1) is a transmembrane protein that is a major regulatory subunit of 
the sodium pump (Na/K ATPase) function in cardiac cells and a major target for PKA and 
PKC mediated regulation of the pump.  FXYD1 may be S-acylated at two cysteines (C40 
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and C42) in its short intracellular N-terminus (256). S-acylation has neo effect on FXYD1 
membrane expression but S-acylation increases the half-life of FXYD1 expression.  
Importantly, S-acylation was essential for FXYD1 to mediate inhibition of pump activity: non- 
S-acylated FXYD1 was unable to inhibit pump activity. Furthermore, PKA dependent 
phosphorylation of FXYD1 downstream of the sites of S-acylation promoted FXYD1 S-
acylation. Other members of the FXYD family are also predicted to be S-acylated and thus 
may control pump activity in other tissues via a S-acylation dependent mechanism. 
An intriguing function of S-acylation in transporter function is to control distinct functions of 
phospholipid scramblases (PLSCR) 1 & 3. PLSCR1 is a calcium-binding protein that controls 
phospholipid transfer across the plasma membrane.  PLSCR1 contributes to the 
reorganisation of lipids in a number of cell types including platelets and red blood cells in 
particular in response to elevated intracellular calcium in response to cell injury or apoptosis. 
PLSCR1 is multiply S-acylated in a core ±184CCCPCC- motif that targets it to lipid raft 
domains and is essential for trafficking to the plasma membrane (267). In contrast, de-
acylated PLSRC1 is targeted to the nucleus where it can bind DNA and activate 
transcriptional cascades. Under normal conditions the large majority of PLSCR1 is located in 
the plasma membrane or endosomal membranes. The ability of S-acylation to act as a 
switch of PLSCR1 function is important following the rapid upregulation of PLSCR1 
expression following exposure to cytokines when newly synthesised PLSCR1 rapidly 
accumulates in the nucleus. Intriguingly S-acylation also appears to play a role in differential 
targeting of the scramblase PLSCR3: in this case to the mitochondrion, rather than the 
nucleus. S-acylation of a cluster of five cysteine residues (-159CGCSCCPC-) in PLSCR3 is 
required for mitochondrial localisation in macrophages. At the mitochondrion PLSCR3 
transports cardiolipin from the inner to outer mitochondrial membrane that ultimately results 
in release of cytochrome C into the cytosol and induction of apoptosis. The removal of 
PLSCR3 from the mitochondrion upon de-acylation reduces apoptosis supporting that S-
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acylation of PLSCR3 contributes to the pro-apoptotic function of PSCLR3 in macrophages 
(162).  
 
VI.iv Signalling adapters and chaperones 
The spatial and temporal coordination of cellular signalling cascades is, in large part, 
orchestrated by a diverse array of signalling adapter and chaperone proteins that reulate the 
organisation of macromolecular signalling complexes.  A large number of such adapter 
proteins are S-acylated and we are beginning to understand some of the roles of S-acylation 
in controlling information flow through these signalling networks.  
PSD-95 is the most abundant abundant scaffolding protein in the post-synaptic density of 
glutamatergic chemical synapses where it coordinates the assembly of a variety of ligand-
gated ion channels (including AMPA and NMDAR) and other signalling proteins and 
transmembrane adhesion molecules essential for the correct assembly and function of 
glutamatergic chemical synapses.  PSD-95 is S-acylated at its N-terminus on two residues 
by multiple zDHHC enzymes including zDHHC2, and is essential for its post-synaptic 
targeting (61, 252). PSD-95 S-acylation appears to play a primary role in assembly and 
maturation of dendritic spines through establishment of domains of PSD-95 and its 
interacting molecules.  Recent evidence, exploiting a conformation specific antibody that 
recognises the S-acylated conformation of PSD-95, revealed local acylation-deacylation 
cycles of PSD-95, driven by zDHHC2, serve to create nanodomains of clustered PSD-95 
that are maintained in the postsynaptic membrane of dendritic spines (62).  Importantly, 
activity-dependent remodelling and expansion of the PSD involves establishment of new 
PSD-95 nanodomains driven by increases in plasma membrane inserted zDHHC2 (62) that 
allow recruitment and stabilisation of PSD-95 into the nanodomains. Such PSD remodelling 
is thought to be central to the mechanisms underlying synaptic plasticity at synapses. 
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Ankyrin-G is another adapter protein that interacts with multiple transmembrane proteins 
anchoring them to the sub-membrane network of EII-spectrin and actin.  Ankyrin G is S-
acylated towards its N-terminus, via zDHHC5 and 8, allowing Ankyrin-G to localise to the 
lateral membrane of polarized columnar epithelial MDCK cells. (88, 89)   Knockdown of 
zDHHC5 and 8, or site directed mutagenesis of the Ankyrin±G S-acylated cysteine mimics 
the effect of Ankyrin-G knockout itself: preventing lateral membrane assembly and thus 
significantly reducing epithelial cell height.  Intriguingly, this mechanism is also dependent 
upon phospholipid interactions with EII-spectrin, that binds to Ankyrin-G, in micron-sized 
domains in the lateral membrane in which zDHHC5 and 8 are also co-localised (88). EII-
spectrin mutants that cannot bind Ankyrin-G or phospholipids also disrupt lateral membrane 
assembly.  This highlights that an important interaction between two distinct lipid±dependent 
mechanisms is required for lateral membrane assembly: S-acylation of the adapter protein 
Ankyrin-G and phospholipid binding to its binding partner EII-spectrin. Whether such a 
mechanism also controls assembly of other Ankyrin-G dependent complexes, such as at the 
axon initial segment, and how assembly controls lateral membrane assembly, perhaps 
through control of adhesion molecules, that control intercellular contacts, remains to be 
explored.  
The large family of cAMP-dependent protein kinase A (PKA) anchoring proteins (AKAPs) 
allow efficient signalling through PKA signalling pathways. Several members of the AKAP 
family are S-acylated and target PKA (via binding to the regulatory R subunits) to multiple 
effectors as well as other components of the signalling machinery. For example, the small 
AKAP15/18 targets PKA to the plasma membrane to promote PKA-dependent regulation of 
L-type calcium channels in neurones, endocrine and cardiac cells (58, 70). In hippocampal 
neurones, activity-dependent S-acylation of the multi-functional AKAP79/150 at two sites 
(C36 and C129) within its N-terminal polybasic domain targets AKAP79/150 to lipid rafts and 
recycling endosomal membranes in dendrites (123). This recruitment was important for 
AMPAR recruitment and synaptic plasticity, in part likely due to the role of AKAP79/150 in 
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coordinating AMPAR phosphorylation, as AKAP79/150 mutants that lack the S-acylation site 
do not support AMPAR trafficking and synaptic potentiation in vitro. In other systems, this S-
acylation dependent recruitment of AKAP79/150 to lipid rafts, from non-raft domains, 
promotes assembly with the calcium-dependent adenylate cyclase, AC8 (41) to coordinate 
PKA-dependent phosphorylation of multiple raft proteins upon store-operated calcium entry. 
Transmembrane adapter proteins (TRAPs) represent a large and diverse family of proteins 
that can coordinate signal transduction modules at the plasma membrane (236).  A 
significant number of TRAPs have been reported to be S-acylated, with linker of T-cell 
activation (LAT) representing a protypical TRAP expressed in T-cells, as well as other cells 
of the immune system, and important for T-cell receptor signalling. S-acylation of two 
juxtamembrane cysteine residues (C26 & C29) in LAT are required for its partitioning into 
lipid rafts with either mutation of the cysteines or pharmacological inhibition of S-acylation 
disrupting raft partitioning (137). S-acylation of C26,that is closest to the plasma membrane 
appears to play the dominant role in raft localisation in model systems again pointing to the 
importance of cysteine positioning for function.  Moreover, mutation of C26 increaseed the 
localisation of LAT on intracellular membranes. Correct raft partitioning is required for 
assembly of LAT with a range of proteins and assembly of a multimolecular signalling 
complex. It is likely that S-acylation of other TRAPs plays a similar role. 
Calnexin is a transmembrane chaperone localised in the endoplasmic reticulum where it 
facilitates the folding of nascent chains of glycosylated proteins and preventing their 
aggregation (see Section III.ii) (132). In addition calnexin plays a role in ER calcium content 
and the regulation of calcium signalling between the ER and mitochondria required for 
control of mitochondrial membrane potential (150, 151).  Recent studies have implicated S-
acylation in controlling these distinct properties, at least in part, by controlling the spatial 
organisation of calnexin in the ER and the assembly of calnexin with distinct protein 
complexes.  Calnexin is S-acylated at two juxtamembrane cysteine residues, predominantly 
C502, and appears to be largely catalysed by zDHHC6 (132, 150). S-acylation of calnexin 
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promotes calnexin localisation to two distinct regions of the ER: i) the perinuclear rough ER 
(RER) that is the site of the ribosome translocon complex (RTC) and ii) the mitochondria-
associated membrane (MAM) that provides communication between the ER and 
mitochondria.  In contrast, de-acylation redistributes calnexin to the tubular ER.  At the RER 
S-acylated calnexin assembles with core components of the RTC leading to recruitment of 
the actin cytoskeleton and stabilisation of the super-complex (132). S-acylation of calnexin at 
the RTC is thus essential for the ability of calnexin to perform its chaperone function and 
capture nascent polypeptides and promote their folding as they emerge from the translocon.  
Inhibition of zDHHC6 or mutation of the calnexin S-acylatied cysteines disrupts glycoprotein 
folding.  In contrast, at the MAM, S-acylated calnexin assembles with the sarcoplasmic 
reticulum ca2+-transport ATPase 2b (SERCA2b) and reduces the ability of mitochondria to 
uptake Ca2+ from the ER (151).  De-acylation of calnexin prevents its association with 
SERCA2b with subsequent loss of the inhibitory effect of calnexin on mitochondrial Ca2+ 
uptake from the ER.  Importantly, following a short term ER stress calnexin becomes de-
acylated thus shifting its function away from Ca2+ homeostasis and promotes its ER quality 
control functions, for example by interaction of de-acylated calnexin with the oxidoreductase 
ERp57. Taken together these data indicate S-acylation as an important switch to allow 
differential localisation and functions of calnexin in the ER with impacts on both protein 
folding and mitochondrial homeostasis.  
 
VI.v Transcriptional regulation 
Increasing evidence suggests that S-acylation may control transcription through a variety of 
mechanisms.  As outlined above, S-acylation of steroid receptors can determine whether the 
receptor acts as a receptor at the plasma membrane (S-acylated receptor) or conversely 
controls transcription via DNA binding in the de-acylated state (130, 189-191). Recent 
evidence also points to S-acylation controlling translocation of another transcription factor, 
nuclear factor of activated T-cells 5a, NFAT5a, from the plasma membrane to the nucleus to 
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control gene transcription (50). NFAT5a is myristoylated and S-acylated at its N-terminus 
with S-acylation being required for the localisation of NFAT5a at the plasma membrane 
under conditions of cells in the isotonic state.  However, upon osmotic stress NFAT5a is 
released from the plasma membrane and translocates to the nucleus, a process that likely 
requires de-acylation as site-directed mutants that lack the S-acylated cysteine, but not 
myristoylated residue, or acute inhibition of S-acylation with 2-BP, result in NFAT5a being 
located in the nucleus.  
Transcription requires remodelling of chromatin structure in the nucleus, a process intricately 
controlled by the post-translational regulation of histones, including by methylation and 
acetylation. Recent proteomic screens of S-acylation substrates in Jurkat cells revealed that 
a number of histone H3 variants, including H3.2, are S-acylated with the conserved cysteine 
C110 being a major site of S-acylation (268). The functional impact of H3 S-acylation has yet 
to be fully established although the localisation of H3 to the nuclear shell fraction in HeLa 
cells may support a role in perinuclear tethering of chromatin, a process associated with 
inactive heterochromatin. Intriguingly, 2-BP treatment of P19 mouse embryonic carcinoma 
cells impaired neuronal differentiation and cell cycle exit with associated changes in H3, and 
Histone 4 (H4), acetylation (34). This suggests that S-acylation may, directly or indirectly 
control histone acetylation and hence chromatin remodelling. Of note, H4 has also been 
reported to be O-acylated on serine 47 (S47) by nuclear localised acyl-CoA: 
lysophosphatidylcholine acyltransferase (Lpcat1) via a calcium-dependent mechanism (293). 
Knockdown of Lpcat1, the cytosolic form of which also catalyzes an acyltransferase reaction 
by adding a palmitate to the sn-2 position of lysophospholipids, or the H4 S47A mutant 
decreased global mRNA synthesis.  
 
VI.vi Enzymes and kinases 
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S-acylation is now implicated in controlling a wide diversity of protein and lipid kinases as 
well as an eclectic array of other enzymes and signalling proteins. 
VI.vi.a Tyrosine kinases 
Perhaps the best studied examples of S-acylated protein kinases are members of the Src-
family of non-receptor tyrosine kinases (SFK) implicated in a wide diversity of signalling 
responses including cell proliferation, changes in cell-morphology and migration as well as 
differentiation.  Members of the family are co-translationally myristoylated at glycine residue 
2 but are differentially S-acylated at cysteine residues immediately downstream of the 
myristoylated glycine (127). For example, Src-kinase is not S-acylated, whereas Lyn and 
Yes kinases are mono-acylated at C3 whereas Fyn is S-acylated at both C3 and C6 cysteine 
residues. The subcellular organisation of these kinases is important for their functional role 
and the degree of S-acylation has been proposed to control the mode of SFK trafficking and 
predominant subcellular localisation. In an elegant series of studies, exploiting both site-
GLUHFWHGPXWDQWV DQGF\VWHLQH µNQRFN-LQ¶ H[SHULPHQWV Sato and co-workers revealed three 
distinct modes of SFK trafficking (217). Non S-acylated SFKs, such as Src, enter a rapidly 
recycling pathway between endosome and the plasma membrane that is controlled by 
myristoylation. In contrast, SFKs that may be singly S-acylated, such as Lyn and Yes are S-
acylated in the Golgi apparatus where they enter the secretory pathway for delivery to the 
cell surface. In this case, if Lyn or Yes are not S-acylated they remain largely in the Golgi 
apparatus due to their myristoylation. In contrast, dually S-acylated Fyn is targeted directly to 
the plasma membrane. Introduction of an addition S-acylated cysteine in Yes, or mutation of 
just C6 in Fyn, resulted in the respective mutant SFKs entering the dually- or mono- S-
acylation pathways respectively.  Taken together, at least for these peripheral membrane 
proteins, the extent of S-acylation acts as a postcode to direct the kinases to distinct 
compartments.  For most SFKs the repertoire of zDHHCs that control S-acylation are not 
well established. For Fyn, zDHHC21 has been identified as a candidate and in mice with a 
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loss of function mutation in zDHHC21 Fyn is mislocalised in hair follicles and mice have 
significant hair loss (163) 
VI.vi.b Lipid kinases 
Phosphatidylinositol 4-phosphate (PI4P) is an important phospholipid required for Golgi 
membrane trafficking and control of phosphoinositide biosynthesis and signalling at the 
plasma membrane. At the Golgi, PI4P is predominantly synthesised by the lipid kinase 
phosphatidinylinositol 4-kinase IID (PI4KIID) that is very tightly associated with the 
membrane even though it lacks any transmembrane domains. PI4P assembles with 
zDHHC3 and 7 in lipid raft domains in the Trans-Golgi network in a cholesterol dependent 
mechanism (149). zDHHC3 and 7 S-acylate multiple cysteines in the 173CCPCC motif within 
the catalytic core of  PI4KIID that is essential for both assembly with the zDHHCs and 
localisation in lipid raft domains (15, 149). Mutation of these cysteines, or knockdown of the 
cognate zDHHCs also significantly reduces PI4P kinase activity and consequently Golgi 
PI4P levels.  
VI.vi.c RAS superfamily of small GTPases 
The rat sarcoma (Ras) superfamily of small GTPases, comprising Rac, Rho, Rab, Arf and 
Ran subfamilies are important signal transducers that act as switches to control a diverse 
array of downstream effectors and regulate a variety of physiological mechanisms including 
cell growth, movement, differentiation and survival.  
The importance of S-acylation of H-Ras and N-Ras, in conjunction with prenylation, in 
controlling their trafficking and localisation at the plasma membrane to mediate effective 
signalling has long been recognised (for review see (144).  Importantly, H- and N-Ras 
plasma membrane targeting is intricately controlled by cycles of S-acylation and de-acylation 
coordinated through the activity of predominantly Golgi-localised zDHHCs and 
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palmitoylthioesterases at other internal membranes to promote accumulation of these 
GTPases at the plasma membrane (40, 209, 258). 
The Rho GTPase Rac1 is also S-acylated but at a cysteine residue (C178) in the C-terminus 
that is more proximal than the cysteine residues of H- and N-RAS that are located adjacent 
to the prenylated ±CAAX box (176). S-acylation is required for correct localisation of Rac1 in 
lipid rafts at the plasma membrane and de-acylated Rac1 shows reduced GTP loading and 
increased oligomerization, with reduced activation of its downstream effector PAK kinase 
leading to defects in cell spreading and migration. Another intriguing variation on this theme, 
that also highlights the importance of alternative splicing in determining S-acylation of many 
proteins, is the example of the Rho GTPase Cdc42 (122).7KHµFDQRQLFDO¶&GFVSOLFHIRUP
is ubiquitously expressed and membrane association is determined by prenylation of the C-
terminus and differs from H-Ras and N-Ras in lacking the C-terminal S-acylation sites. 
However, a brain specific C-terminal splice variant replaces the C-terminal prenylation motif 
to a sequence with a di-cysteine motif (-CCAX) just upstream of the C-terminus. This brain 
specific isoform (bCdc42) was reported to be S-acylated and preferentially targeted to 
dendritic spines, compared to the canonical variant that locates in both spines and dendritic 
shaft. The S-acylated bCdc42 variant being more efficient at promoting spine remodelling in 
cultured neurones based on studies using mutants of both cysteines in the ±CCAX terminus. 
However, functional diversity of the bCdc42 variant is expanded further as bCdc42 can exist 
in two forms via a novel form of ±CAAX processing (178): a form that is tandemly prenylated 
and S-acylated, as it bypasses the canonical post-prenylation steps of proteolysis and 
carboxymethylation, with S-acylation occurring on the second cysteine of the ±CCAX 
WHUPLQXV DQGD µFDQRQLFDO ±&$$;¶SURFHVVHG IRUPRI E&GF What is not S-acylated. The 
dually prenylated and S-acylated form of bCdc42 does not interact with RhoGDID thus 
promoting the amount of bCdc42 at the plasma membrane and potentiating bCdc42 
signalling.  
VI.vi.d Other enzymes 
58 
 
Superoxide dismutase 1 (SOD1) is a ubiquitously expressed protein that protects cells from 
oxidative damage and mutations are associated with the familial variant of Amyotrophic 
lateral sclerosis (Lou Gehrig disease) as well as other disease of oxidative damage including 
artherosclerosis and diabetes. In endothelial cells, SOD1 is S-acylated on an N-terminal (C6) 
cysteine residue that, based on crystal structures of the mature protein is normally buried 
within the protein; this cysteine is also associated with other cysteine-dependent 
interactions, including disulphide bond formation (155). Whether C6 is S-acylated in the 
mature protein or in the apo-protein, in which C6 is thought to be exposed, remains to be 
determined. Several mutations of C6 are found in ALS patients with increased aggregation 
of SOD1, and thus S-acylation of C6 has been proposed as a potential protective 
mechanism especially in the aggregate prone apoprotein (155). In endothelial cells, S-
acylation of SOD1 is mediated predominantly via zDHHC21 and zDHHC21 knockdown, or 
C6S mutation, reduces SOD nuclear localisation and enzyme activity (155). 
S-acylation is also an important determinant of the function of several enzymes that produce 
gaseous transmitters such as nitric oxide (NO) and carbon monoxide (CO).  For example, in 
endothelial cells endothelial nitric oxide, eNOS is the major enzyme controlling nitric oxide 
production that is essential for vascular function. eNOS is dually myristoylated and S-
acylated (C15 and C26), largely through zDHHC21 in endothelial cells, although several 
other enzymes can S-acylate eNOS in overexpression assays (54, 64, 146). S-acylation is 
crucial for eNOS to be targeted to the plasma membrane and caveolae as zDHHC21 
knockdown or site directed mutation of C15 and C26 results in a more perinuclear and Golgi 
localisation of the enzyme (54).  Furthermore, inhibition of eNOS S-acylation abrogates both 
basal and stimulated NO synthesis in endothelial cells. S-acylation is also important for 
targeting haem oxygenase 1 to the mitochondrial associated membrane region of the ER as 
disruption of HMOX1 S-acylation redistributed the enzyme to other ER localisations (150).  
HMOX1 degrades haem to produce the anti-apoptotic gas carbon monoxide that is also an 
important determinant of mitochondrial and ion channel function. However, whether S-
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acylation also controls HMOX1 activity per se, in addition to its role in HMOX1 localisation, is 
currently not known. 
Enzymes involved in termination of signalling cascades are also regulated by S-acylation 
with the phosphodiesterase 10A (PDE10A) being another remarkable example of how S-
acylation works with other PTMs to control function (32). PDE10A is a dual (cAMP and 
cGMP) cyclic nucleotide PDE that is highly enriched in the striatum. PDE10A inhibitors and 
mouse models have implicated this PDE as a potential ant-psychotic strategy for disorders 
such as schizophrenia through compartmentalisation of cyclic nucleotide signalling 
cascades. PDE10A exists as two N-terminal splice variants: the longer PDE10A2 variant is 
predominantly membrane localised, including at postsynaptic membranes, that is controlled 
by S-acylation of C11. S-acylation of PDE10A2 is largely mediated via zDHHCs 7 & 19 in 
overexpression assays and mutation of C11 in PDE10A2, or the shorter PDE10A1 variant 
that lacks C11, has a cytosolic localisation and reduced trafficking to distal dendrites (32).  
Importantly, S-acylation of PDE10A2 is inhibited by PKA, or PKG, mediated phosphorylation 
of a Threonine residue (T16) immediately downstream of the S-acylated cysteine. Thus 
elevations of cAMP, or cGMP, prevent PDE10A2 S-acylation and trafficking to the 
membrane although acute stimulation of these pathways does not remove PDE10A2 already 
resident at the plasma membrane (32).  
S-acylation is also implicated in the control of enzymes involved in proteolytic processing as 
evidenced by the amyloid precursor protein (APP) processing enzymes aspartyl protease E-
site APP-cleaving enzyme 1 (BACE1) and the multi-protein complex J-secretase. APP 
processing involves sequential proteolysis by BACE1 and J-secretase to generate AE 
peptides that accumulate in the brains of patiHQWV ZLWK $O]KHLPHU¶V GLVHDVH %$&( LV 6-
acylated at four cysteine resides at the junction of transmembrane and cytosolic domains 
DQGFRQWUROV%$&(ORFDOLVDWLRQWRµOLSLGUDIWV¶DVVLWHGLUHFWHGPXWDJHQHVLVRIWKHVHUHVLGXHV
localised BACE1 to non-raft domains (263). However, although S-acylation controlled raft 
localisation, it had no effect on APP processing suggesting that BACE1 activity is similar in 
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both raft and non-raft domains. A similar mechanism, to control lipid raft localisation, with 
little if no effect on processing, is also observed with the effects of S-acylation of J-secretase 
(35). Two subunits of J-secretase, Nicastrin and APH-1, are S-acylated with Nicastrin S-
acylated at a single site (C689) whereas APH-1 is S-acylated at two sites (C182 & C245). S-
acylation increased stability of Nicastrin and APH-1 and localised J-secretase to detergent 
UHVLVWDQW µOLSLG UDIWV¶ ZLWKRXW DIIHFWLQJ FRPSOH[ DVVHPEO\ (35). However, S-acylation of the 
subunits was not required for processing of APP or other substrates, at least in cultured 
cells. This suggests the role of S-acylation is to protect the two nascent subunits from 
degradation until assembly into the complex (35). APP processing has been reported to be 
controlled indirectly by zDHHC12 by tethering APP at the Golgi membrane and inhibition of 
the generation of APP-containing vesicle and subsequent trafficking to the plasma 
membrane (168). However, the targets for zDHHC12 are unknown, APP itself is unlikely as it 
lacks a cytosolic cysteine residue, moreover, similar effects were seen with a catalytically-
dead zDHHC12 in overexpression assays suggesting the effect of APP trafficking may be 
independent of the acyltransferase activity of zDHHC12. Moreover, the mutant zDHHC12 
also increased non-amyloidogenic D-cleavage of APP. Thus while this highlights another 
possible non-PAT function for zDHHC12, the role of S-acylation in APP processing remains 
elusive. 
 
VI.vii. Cell adhesion molecules: 
An increasing number of cell adhesion molecules (122)  are reported to be S-acylated with 
S-acylation controlling both membrane localisation and signalling including neurofascin, 
integrin-tetraspanin complexes and neural cell adhesion molecules.  
Neurofascin, a member of the L1 family of cell adhesion proteins, is S-acylated at a 
conserved cysteine residue (C1213) in the predicted membrane spanning domains. S-
acylation did not affect neurofascin membrane localisation, targeting to axons nor its ability 
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to interact with the adapter Ankyin-G or cell-adhesion activity in neuroblastoma cells. 
However, S-acylation targeted neurofascin to low density membrane compartments 
resembling caveolae (204).  
S-acylation also plays a complex role in controlling the formation of membrane 
microdomains enriched for tetraspanins and a variety of integrins that control cell 
morphology, migration and signalling. Tetraspanins and integrins can assemble into complex 
signalling networks dependent upon both S-acylation of individual tetraspanins and integrins. 
For example, S-acylated integrins (D3, D6 and E4) can coexist with a number of tetraspanins 
such as CD9, CD63 and CD81. E4 integrins are S-acylated at multiple cysteine residues and 
that E4 integrins cannot be S-acylated result in disruption of both integrin and tetraspanin 
interactions, clustering of tetraspanins, as well as integrin signalling and control of cell 
morphology (277).  
The S-acylation of NCAMs themselves can also be dynamically regulated to control axonal 
outgrowth and targeting. In neuroblastoma cells, the two major NCAM isoforms NCAM140 
and NCAM180 are S-acylated and this can be stimulated by FGF2-mediated signalling 
through the FGF receptor (197). This mechanism appears to involve elevation of zDHHC7 
activity that is the major zDHHC S-acylating these NCAMs.  The NCAMs are S-acylated at 
multiple cysteine residues that targets the NCAM to lipid rafts and subsequent downstream 
signalling through tyrosine focal adhesion kinase and extracellular signal regulated 1/2 
kinase to stimulate neurite outgrowth (177). Deleted in colorectal cancer (DCC) is 
homologous to neuronal cell adhesion molecules (NCAM) and is a receptor for the guidance 
molecule netrin-1 that controls commissural axons in the developing nervous system. DCC 
is S-acylated at a juxtamembrane cysteine that is important for targeting DCC to lipid rafts 
and this S-acylation dependent targeting is required for netrin-1 signalling to ERK and 
neurite outgrowth (99).   
62 
 
S-acylation control of other cell adhesion molecules also plays and important role in non-
neuronal systems. In endothelial cells, the junctional adhesion molecule platelet endothelial 
cell adhesion molecule-1 (PECAM1, CD31), is S- acylated by zDHHC21 on C595 although 
zDHHC3 may play a role in other cell types such as HEK293 cells. Knockdown of zDHHC21 
leads to a significant reduction in PECAM1 surface expression although this is associated 
with a decrease in total PECAM1 expression suggesting S-acylation controls PECAM1 
stability (155). As PECAM1 is implicated in a diverse array of endothelial function from 
angiogenesis to flow sensing and transepithelial cell migration change sin S-acylation may 
control these important functions of endothelia. 
The examples above illustrate where the cell adhesion molecule itself is S-acylated however, 
control of cell adhesion molecule function may also be controlled by other S-acylated 
proteins they interact with. A recent example, is the activity dependent control of synaptic 
cadherin complexes by its S-acylated binding partner G-catenin and the control of synaptic 
structure and organisation involved in memory formation (19). In hippocampal neurones, 
increases in synaptic activity, for example as observed following protocols that induce long-
term potentiation in vitro, or in vivo such as context-dependent fear conditioning, results in a 
transient increase in G-catenin S-acylation mediated via zDHHC5. S-acylation of G-catenin, 
predominantly at a di-cysteine motif (C960 and C961) in its C-terminus, targets G-catenin to 
the plasma membrane facilitating its recruitment to synaptic clusters of cadherin. The 
functional effect is to stabilise cadherin at the synapse and promote activity dependent 
remodelling of postsynaptic spines and recruitment of synaptic AMPARs resulting in 
increased efficacy of neurotransmission. 
 
VI.viii S-acylated proteins of viruses, protozoa and plants 
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The discussion above has focussed on the role of S-acylation in predominantly mammalian 
systems. However, S-acylation plays a critical role in a diverse array of species from viruses 
to protozoans and plants, although bacteria lack the machinery for enzymatic S-acylation.  
Viral proteins were the first S-acylated proteins identified (221). Since then several classes 
of viral protein have been shown to be S-acylated including: spike proteins involved in 
membrane fusion (such as hemagluttinin (HA)) from influenza virus Viruses; viroporins such 
as the M2 ion channel protein of Influenza and; a variety of peripheral membrane proteins 
(for review see (260)). Although the role of S-acylation is not fully understood in many cases 
S-acylation plays a role in targeting viral proteins to lipid raft domains and controlling aspects 
of virus entry into host cells by controlling spike protein mediated membrane fusion events 
as well as subsequent virus assembly and release from cells. In contrast to many cellular S-
acylated proteins, most viral proteins do not appear to undergo cycles of S-acylation and de-
acylation, most likely reflecting that viral proteins are used only once in the viral lifecycle.  
Furthermore, the cellular enzymes that control viral protein S-acylation are ill defined, 
although as viral protein S-acylation occurs at the ER and Golgi it is likely to be a subset of 
the zDHHCs localised to these sites. Intriguingly, S-acylation is also important for host 
resistance to influenza viral infections. For example, S-acylation of interferon-induced 
transmembrane protein 3 (IFITM3) is required for its membrane clustering and antiviral 
activity (282).  
S-acylation plays a major role in all aspects of the lifecycle and function of the 
trypanosomatids, eukaryotyic single-celled flagellated protozoans, including the major 
VSHFLHVLQYROYHGLQKXPDQGLVHDVHVVXFKDVWKH/HLVKPDQLD¶V&KDJDVGLVHDVe and African 
sleeping sickness (for review see (66)). For example, proteomic screens have identified > 
100 S-acylated proteins in Trypanosoma brucei (53) and global inhibition of S-acylation is 
lethal to these organisms.  
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The major cause of mortality in malaria infection, Plasmodium falciparum, also expresses a 
large (>400) compliment of S-acylated proteins several of which are involved in controlling 
the actin-myosin machinery required for these organisms to invade red blood cells of 
infected individuals and for asexual development (118). S-acylation has also been shown to 
play multiple roles in the lytic cycle of another member of the same phylum, Toxoplasma 
gondii, the causative agent of toxoplasmosis (see (59)). 
A large number of S-acylated proteins have been identified in Yeast (Saccharomyces 
cerevisiae) including many proteins involved in vesicle fusion/trafficking and amino acid 
transport (212). In S. pombe the level of Erf2 DHHC activity controls meiotic entry with high 
Erf2 activity promoting meiosis, in part through S-acylation of the small GTPase Rho3 
whereas low Erf2 activity delays entry into meiosis (285). S-acylation also controls telomere 
dynamics in yeast as S-acylation, via the DHHC Pfa, targets the telomere interacting protein 
Rif-1 to discrete foci at the periphery of the inner nuclear membrane allowing assembly of 
µWHORPHUHFOXVWHUV¶DQGVXEVHTXHQWUHJXODWLRQRIWHORPHUHG\QDPLFVDQGVLOHQFLQJ(187). 
More than 500 S-acylated proteins have been identified in Arabidopsis root cells (95) and S-
acylation is emerging as a major signalling pathway controlling multiple aspects of plant 
development and growth (96) including development of salt tolerance in Arabdopsis (291) 
 
VII. Conclusions and perspectives 
In this review we highlighted the key features of protein S-acylation, highlight the diversity of 
proteins controlled by this essential post-translational modification and the physiological 
function of S-acylation in health and disease.  As we outline, major goals, opportunities and 
challenges are to understand: 
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i) the mechanisms by which S-acylation is controlled, how covalent addition of lipid 
can control diverse properties of proteins and how this is spatiotemporally 
coordinated. 
ii) the physiological relevance of S-acylation at a systems and whole organism level.   
To address these issues it is clear that new tools are urgently required. However, the recent 
development of new proteomic, chemical biology, imaging and genetic tools are enabling 
studies to understand and interrogate S-acylation at multiple levels of analysis.   
Key questions for the future that need to be addressed include: 
i) How is zDHHC substrate specificity and activity controlled? A key challenge is to 
understand how zDHHCs themselves are regulated by post-transcriptional (e.g. 
mRNA splicing) and post-translational regulation, including by S-acylation itself. 
How are substrates recognised and how is this spatiotemporally coordinated?  
ii) Can we pharmacologically control distinct zDHHC and APTs? No specific 
inhibitors or activators of zDHHCs exist although a limited number of 
acylthioesterase inhibitors are now being explored. Targeting zDHHC will be a 
major challenge, in particular as we have no structural determination of any 
zDHHC to guide rationale drug design. 
iii) How is de-acylation controlled? The acyl thioesterases that control de-acylation 
and the spatiotemporal dynamics of de-acylation of most proteins is unknown. It 
is likely that several members of the larger serine hydrolase superfamily also 
function as deacylating enzymes for a range of proteins.  
iv) When and where does S-acylation occur? Recombinant zDHHCs may be 
localised in multiple compartments including the ER, Golgi and plasma 
membrane but for most zDHHCs we do not know the subcellular distribution of 
zDHHCs in native cells.  The lack of high quality antibodies against zDHHCs 
remains a major bottle neck. Furthermore, determining the cellular compartments 
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where specific proteins are S-acylated/de-acylated remains a significant 
challenge. The spatiotemporal dynamics of S-acylation for most proteins is very 
poorly understood and improved tools to quantify the spatiotemporal dynamics 
are required. 
v) How does S-acylation integrate with other post-transcriptional and post-
translational modifications to control cellular function? It is clear that significant 
cross-talk between S-acylation and other signalling pathways may occur. Insight 
into the rules, mechanisms and cross-talk of S-acylation with these modifications 
has broad implications for cellular signalling.  
vi) What is the functional impact of S-acylation at the systems/whole organism level? 
With recent developments of genome editing tools we now have the opportunity 
to interrogate the functional impact of S-acylation, and its disruption, on 
physiological homeostasis. For example, few studies have exploited µWDUJHW-
protein-FHQWULF¶HJVLWH-directed mutagenesis of S-acylated cysteines) as well as 
µ6-DF\ODWLRQ FHQWULF¶ HJ NQRFNRXW RI VSHFLILF ]'++& DFWLYLW\ DSSURDFKHV WR
understand how S-acylation controls the physiological function of key S-acylated 
proteins.  Furthermore, more rigorous development and analysis of global and 
conditional zDHHC knockout animals should provide insight into both the array of 
proteins controlled by distinct subsets of zDHHCs as well as the physiological 
processes controlled by these enzymes.   
vii) Is S-acylation disrupted in disease? While disruption of S-acylation has been 
associated with a variety of major disorders our understanding of how S-acylation 
may be dynamically controlled during normal ageing, in response to homeostatic 
challenge, or how it is disrupted in disease states remains rudimentary. A clearer 
understanding of loss of S-acylation regulation will be key to defining potential 
therapeutic opportunities to manipulate S-acylation and its associated pathways 
in disease. 
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We hope this review provides further impetus for both established S-acylation investigators 
to address these issues as well as to provide a platform for investigators new to the field to 
explore the scope and opportunities to understand the physiology of S-acylation. The 
development of new tools has the potential to provide a paradigm shift in our understanding 
of the physiology of S-acylation and the promise of potential new therapeutic avenues for a 
diverse array of major human disorders.  
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Figure legends 
Figure 1: Major lipid modifications of proteins. 
S-acylation is reversible due to the labile thioester bond between the lipid (typically, but not 
exclusively, palmitate) and a cysteine amino acid of a protein. The zDHHC family of 
palmitoyl acyltransferases mediate S-acylation. Other major lipid modifications result from 
stable bond formation between either the N-terminal amino acid (amide) or the amino acid 
side chains in the protein (thioether, and oxyester). Distinct enzyme families control these 
lipid modifications: N-myristoyltransferase (NMT) controls myristoylation of many proteins 
such as the src-family kinase, Fyn kinase; amide-linked palmitoylation of the secreted sonic 
hedgehog protein is mediated by Hedgehog acyltransferase (Hhat), a member of the 
membrane bound O-acyl transferase (MBOAT) family. Prenyl transferases catalyse 
farnesylation (farnesyltransferase, FTase) or geranylgeranylation (geranylgeranyl 
transferase I and II, GGTase I and II) of small GTPase proteins such as RAS and the Rab 
proteins respectively. Porcupine (Porcn) a member of the MBOAT family acylates secreted 
proteins such as Wnt.  
 
Figure 2: Protein S-acylation: a reversible lipid post-translational modification 
controlled by the zDHHC family of acyltransferases 
a) zDHHC enzymes typically utilise co-enzyme A (CoA)-palmitate however, other long chain 
fatty acids (either saturated or unsaturated) can also be used. Deacylation is mediated by a 
number of acyl thioesterases of the serine hydrolase family. b) Phylogenetic tree showing 
the relationships of the DHHC-CR domain of the 23 human zDHHC acyltransferases that are 
c) predicted transmembrane proteins (typically with 4, or 6, transmembrane domains) with 
the catalytic DHHC domain located in a cytosolic loop. 
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Figure 3: Location of sites of S-acylation in transmembrane and peripheral-membrane 
proteins. 
Schematic illustrating different locations of cysteine S-acylation in transmembrane and 
peripheral membrane proteins.  In many cases S-acylation allows a terminus or loop of a 
protein to associate with the membrane interface. S-acylation can also confer structural 
constraints in particular when located close to transmembrane domains where S-acylation 
has been proposed to control transmembrane orientation that may be important for 
controlling hydrophobic mismatch in different sub-cellular membrane compartments. 
 
Figure 4: S-acylation and regulation of the protein lifecycle 
Reversible S-acylation regulates multiple steps in the lifecycle of membrane and peripheral-
membrane proteins including: assembly and (a) ER exit; (b) maturation and Golgi exit; (c) 
sorting and trafficking to target membranes;  (d) recycling and internalisation; (e) clustering 
and localization in membrane microdomains; (f) control of properties and regulation by other 
signalling pathways; (g) partitioning of peripheral membrane proteins between the cytosol 
and membranes and; (h) recycling and final degradation.  
 
Figure 5: Diversity of S-acylated proteins 
Schematic illustrating the diversity of proteins demonstrated to be S-acylated. A large 
number of proteins identified to date are involved in cellular transport and signalling although 
structural, chaperone, cell adhesion and proteins required for translational/transcription are 
also S-acylated.  
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